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Abstract	  
 
 
STAT3 (signal transducer and activator of transcription-3) is activated by 
numerous cytokines and growth factors. As a transcription factor, STAT3 
plays important roles in many processes including embryonic development, 
immunity and different types of cancer progressions. 
In response to cytokine stimulation, STAT3 is activated through 
phosphorylation of a single tyrosine residue. The phosphorylated STAT3 
molecules dimerize via a reciprocal interaction between the phosphorylated 
tyrosine of one and the SH2 (Src homology 2)-domain of the other 
monomer, accumulate in the nucleus and bind to specific DNA sequences, 
which is followed by the target gene expression. 
In addition, STAT3 is able to dimerize in the absence of cytokine 
treatment. However the structural background and the function of these 
preformed dimers are not known. 
We analyzed the structural organizations and requirements of the 
nonphosphorylated and phosphorylated STAT3 dimer associations using 
fluorescence based microscopy techniques as dual-focus fluorescence 
correlation spectroscopy (2f-FCS) and Förster resonance energy transfer 
(FRET). 
Results presented in this thesis reveal the similar parallel associations of 
the non-activated and activated STAT3 dimer forms, however the dimers 
are stabilized by diverse interdomain interactions. 
We demonstrate the importance of the N-terminal domain in dimerization 
of latent STAT3, moreover we showed that this dimer is mostly stabilized 
by homotypic interactions between the N-terminal fragments, similar to 
other STAT family members.  
In addition, we identified a single residue (L78) in the N-terminal domain 
of STAT3 promoting this dimerization, but also the tetramerization of the 
molecules on specific DNA sequences.  
We showed that inhibition of latent STAT3 dimers positively affects the 
phosphorylation of STAT3, demonstrating the importance of preassociation 
in the negative regulation of STAT3 activation. 
These structural findings reveal the unique structural characteristics of 
STAT3 in the STAT family and partially explains the different 
biochemical features, functions and the constitutive activation in various 
diseases of this very important transcription factor. 
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1.	  Introduction	  
1.1. 	  Cytokines	  
 
An essential condition for normal functioning of multicellular organisms is 
the existence of a well organized cell-cell communication system. Its 
breakdown can lead to malfunctions and diseases like cancer, chronic 
inflammation, autoimmune disorders or multiple sclerosis (MS). In MS, a 
focal lymphocytic infiltration leads to the damage of myelin in the brain 
and spinal cord [1], driving the neurons unable to effectively conduct 
electrical signals and communicate with each other.  
Two different forms of cell-cell information transfer can be distinguished: 
direct and indirect. Direct communication can be achieved with cytoplasm-
connection of neighboring cells through gap-junctions. The indirect way is 
performed by messenger molecules like hormones, mediators or 
neurotransmitters, which are released by cells and recognized by other 
cells expressing the cognate receptors. Well known members of the 
mediator-system are the cytokines. 
The term „cytokine” was firstly introduced by Stanley Cohen in 1974 for 
mediator substances, which play a role in various aspects of host defense 
[2]. The synonym form interleukin (IL) refers to the capability of acting as 
a communicator between leukocytes. Chemically, cytokines are small (15-
40 kDa), water-soluble glycoproteins, generally acting at low concentrations 
(nano/pico molar range).  
Cytokines are secreted by a high variety of cell types like white blood cells, 
fibroblasts or endothelial cells, and act via binding to specific cell surface 
receptors [3]. Receptor binding leads to the activation of signalling 
cascades, which results in changes in the transcriptional activity of the 
host cell.  
As chemical communicators, cytokines play major roles in mediating and 
regulating immunity, inflammation, hematopoiesis and embryogenesis [3]. 
Dysregulation in the cytokine-driven signalling network can result in 
several diseases and correlates with pathophysological states, as acute 
and chronic inflammatory diseases, neoplastic disorders, cancer and 
autoimmune diseases [4, 5].   
After secretion, cytokines mainly act in two different ways: autocrine 
(effect on the cytokine producing cell) or paracrine (impact on the nearby 
cell). Some members of the cytokine family also have the capability to act 
in an endocrine manner (cytokine effect on distant cell) [6].  
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Special features of cytokine-action are the following: a single cytokine is 
able to act on different types of cells (pleiotropy), similar functions can be 
achieved by different cytokines (redundancy), the effect of two different 
cytokines is stronger than their additive effects (synergy) and they can 
inhibit the effect of other cytokines (antagonism). 
The classification can be based on different aspects. Based on 
functionality, cytokines can be grouped as pro- or anti-inflammatory 
cytokines [7]. On a functional basis and the used receptor system, four 
major group can be formed: interferons, interleukins, growth factors and 
chemokines [8]. 
1.2. 	  Interleukin-­‐6	  (IL-­‐6)-­‐type	  cytokines	  
 
One important subfamily of cytokines is the IL-6-type cytokine family. The 
group is formed by cytokines having similar three-dimensional topology, a 
so called four-helix bundle structure (Figure 1). This motif seems to be a 
common feature in the structure of mediator substances like interleukins, 
interferons and some growth factors, indicating the functional and 
evolutional relationship [9].   
 
 
 
 
Figure 1: Representative crystal structures of  IL-6-type cytokine family members. 
(RCSB Protein Data Bank accession numbers for IL-6, LIF, CNTF and OSM are 1ALU, 
1EMR, 1CNT and 1EVS respectively). 
 
Members of the IL-6 family are: IL-6 (interleukin-6), IL-11 (interleukin-
11), IL-27 (interleukin-27), IL-31 (interleukin-31), LIF (leukaemia 
inhibitory factor), OSM (oncostatin M), CNTF (ciliary neutrophic factor), 
CT-1 (cardiotrophin-1) and CLC (cardiotrophin-like cytokine). These 
cytokines play crucial role in the regulation process of immune and acute 
phase responses, but are also critical in mediating haematopoiesis, 
neuronal regeneration or embryonal development [8]. 
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The signalling procedure follows a combined route with the use of two 
different receptor systems: the short-chain α-receptors and the long-chain 
β-receptors, consisting of 3 or 5-8 immunoglobulin (Ig)/fibronectin-like 
domains, respectively. All family members use the 130 kDa glycoprotein 
(gp130) as signal transducing β-receptor forming homo- or heterodimeric 
complexes. A special case is the IL-31 signalling route, where the cytokine 
binds to a heterodimeric complex, consisting of oncostatin M receptor 
(OSM-R) and a gp130-like protein (GPL) [10]. 
 
 
 
Figure 2: Receptor complexes of the IL-6-type cytokine family. Interleukin-6-type 
cytokines signal through different combination of the receptor subunits (modified from 
Ref. [8]). 
 
Some members of the IL-6 family signal without α-receptor (OSM, LIF, 
CT-1, IL-31). Other cytokines need to have an additional α-receptor 
subunit for the formation of the receptor complex. The α-receptors exist as 
membrane bound forms, as IL-6 receptor (IL-6-R) for IL-6, IL-11 receptor 
(IL-11-R) for IL-11 and ciliary neutrophic factor receptor (CNTF-R) for 
CNTF signalling. In other scenarios, the short-chain receptors are soluble, 
as in the case of IL-27, where the Epstein-Barr virus induced gene (EBI3) 
form together with IL-30 (p28) the composite cytokine IL-27 [10, 11].  
The binding of the cytokine leads to receptor-oligomerization or structural 
changes in the receptor complex, forming a functionally active 
conformation, which is able to initiate the intracellular signalling cascade. 
 
1.3. The	  	  JAK/STAT	  pathway	  
 
The classical, canonical model describes the JAK/STAT pathway in a 
simple and basic form but exhibit some critical points. This hiatus should 
be refined with the non-canonical aspects of JAK/STAT signalling.  
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1.3.1. The	  canonical	  view	  of	  JAK/STAT	  signalling	  
 
In the canonical view, the cytokines are recognized by specific cell surface 
receptors and ligand binding leads to the dimerization of the receptor 
subunits (Figure 3). The cytoplasmic part of the receptors is associated 
with members of the Janus kinase (JAK) family. The receptor 
dimerization brings the JAKs into close proximity, allowing to 
transphosphorylate each other resulting in their activation [12, 13]. The 
activated JAKs subsequently phosphorylate tyrosine residues on the 
receptor, which act as docking sites for proteins containing Src homology 2 
(SH2) domains, as various adaptor proteins (Shc, Grb2) [14], or most 
importantly, transcription factors from the signal transducer and activator 
of transcription (STAT) family. STATs are recruited to the receptor and 
become phosphorylated on a tyrosine residue by JAKs. The phosphorylated 
STATs form dimers (homo- or heterodimers) through a reciprocal 
interaction between the phosphotyrosine motif of one and the SH2 domain 
of the other monomer [15]. The dimerized STAT molecules translocate to 
the nucleus, bind to specific DNA sequences and activate the cytokine-
driven target gene expression [16]. 
 
 
 
 
Figure 3: Canonical JAK/STAT signalling. Ligand binding leads to the dimerization 
of the receptors and the activation of JAKs. Phosphorylated STAT monomers dimerize, 
and the activated dimers translocate to the nucleus to induce target gene expression 
(modified from Ref. [17]). 
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1.3.2. The	  non-­‐canonical	  view	  of	  JAK/STAT	  signalling	  
 
In the non-canonical model the cytokine receptors exist as dimers prior to 
activation (Figure 4), and ligand binding leads to a conformational change 
from an inactive to an active receptor dimer [17].  
In addition, an increasing number of studies demonstrate the existence of 
STAT dimers in unstimulated state, and the capability of STATs to exert 
biological functions independently of phosphorylation [18]. 
These non-canonical functions of STATs were demonstrated in various 
biological processes, as controlling heterochromatin [19] and microtubule 
stability [20], or regulating metabolic functions in mitochondria [21]. 
 
 
 
 
Figure 4: Non-canonical JAK/STAT signalling. Cytokine receptors and STATs are 
also dimerized prior to activation. Preformed STAT dimers are possibly involved in 
biological processes as gene expression regulation. The activation (phosphorylation) 
possibly leads to a stuctural conversion of the STAT dimer from "inactive" to "active" 
dimer conformation (more details of the non-canonical function of STATs see in Ref. [17]). 
  
The inactivation of STAT signalling is achieved by different regulator 
proteins at different stages in the activation cycle such as suppressor of 
cytokine signalling (SOCS) proteins, protein inhibitor of activated STATs 
(PIAS) or tyrosine phosphatases (SHP1, PTP-1B, TC45) [13]. 
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1.4. Signal	  transducers	  and	  activators	  of	  transcription	  (STATs)	  
	  
The name Signal Transducers and Activators of Transcription (STATs) 
refers to dual function proteins which are able to receive the activating 
signal from the cell surface and carry it toward the nucleus to activate 
gene transcription [22]. The first members of the STAT family were 
identified using biochemical separation and purification of factors involved 
in interferon (IFN) induced transcriptional activation [23]. 
The STAT protein family consist of seven members: STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b and STAT6, encoded by different genes, 
localized on three chromosomes [24]. Numerous ligands are able to 
activate STAT transcription factors, including interferons, interleukins, 
growth factors and hormons (Table 1). Primary roles of the protein family 
were defined by gene-targeted removal in mice of each of the seven genes 
[13] (Table 1). 
 
 
 
 
 
Table 1: Functions of the STAT family members. 
The listed ligands induce the activation of the corresponding STAT family member. The 
phenotype describes the effect of the specific STAT gene deletion (adopted and modified 
from Ref. [13]. and Ref. [25]). 
 
STAT family 
member 
Activating ligands Phenotype of null mice 
STAT1 IFN-α, IFN-β, EGF viable, impaired responses to 
interferons 
STAT2 IFN-α, IFN-β viable, impaired responses to 
interferons 
STAT3 IL-6, IL-11, LIF, CT-1, 
CNTF, OSM, EGF,  
G-CSF, leptin 
 
embryonic lethal 
STAT4 IL-12 loss of IL-12 responsiveness 
STAT5a IL-2, IL-3, IL-5, IL-7, 
IL-9, IL-15, Prolactin, 
EPO, TPO, GH, 
G-CSF 
impaired mammary gland 
development 
STAT5b defective NK cell 
development 
STAT6 IL-4, IL-13 loss of IL-4 responsiveness 
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In overall, STATs are playing crucial roles in many processes like 
hematopoiesis, immunity and embryonic developement [17]. The 
dysregulated activation of STAT signalling is involved in chronic 
inflammation [26] and in various malignant progressions of human 
tumors, including blood malignancies (leukaemias/lymphomas) or solid 
tumors (head and neck squamosus cell carcinoma, breast cancer) [27]. 
There are STAT homologues in other species, like in the fruitfly 
Drosophila melanogaster (D-Stat/stat92e or marelle) [28], or in the social 
amoeba Dyctiostelium discoideum, where Dyctiostelium STATs (DdSTATs) 
play critical roles in the early developement and cellular differentiation 
[29]. 
 
1.5. Signal	  transducer	  and	  activator	  of	  transcription	  3	  (STAT3)	  
 
The third member of the STAT family (in order of description) was 
discovered by Wegenka et al. [30] in our institute in 1993 as a nuclear 
factor and termed acute-phase response factor (APRF), which is rapidly 
activated by IL-6. In 1994 Zhong et al. [31] identified STAT3 by cDNA 
library screen as a 92 kDa DNA binding protein which is activated by EGF 
and IL-6, but not by IFN-γ. In the same year, Akira et al. [32] purified and 
cloned APRF/STAT3, that binds to IL-6 responsive elements in promoters 
of acute phase genes.  
1.5.1. Structure	  and	  function	  
	  
The STATs consist of 750-850 amino acids and share a common structural 
organization representing six distinct and functionally conserved domains: 
N-terminal domain (NTD), coiled-coil domain (CCD), DNA-binding domain 
(DBD), linker domain (LD), Src homology 2 (SH2) domain, and the C-
terminally located transactivation (TAD) domain (Figure 5).  
The N-terminal domain was shown to be involved in protein-protein 
interaction [33], dimerization of the non-activated STATs [34], but also in 
tetramerization on specific gene promoters [34, 35]. 
The CCD domain adopts an elongated structure, formed by a 4-helix 
bundle, connected with short loops [15], has a functional role in the 
interaction with other proteins like c-JUN [36], but is also implicated in 
STAT3 receptor recruitment and binding [37]. 
The DNA-binding domain is localized in the central region of the molecule 
and contains the amino acid residues that interact with specific enhancer 
sequences in the promoter region of target genes. 
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The linker domain has a small helical structure which connects the DNA-
binding domain to the SH2 domain. 
The SH2 domain contains the binding site for phosphotyrosine (pTyr) 
motifs and is therefore essential for binding to the activated receptor [38], 
and required for the activated dimer formation through reciprocal 
intermolecular interaction between the pTyr and SH2 domain of two 
monomers [39]. 
The transactivation domain (TAD) is a structurally disordered, highly 
flexible, natively unfolded domain [28]. TAD participates in protein-
protein interactions [40] but is also involved in an intramolecular 
interaction with CCD and SH2 domains, which might be crucial for 
receptor binding [41]. 
 
 
 
 
 
Figure 5: STAT family members and their functional domains. The STATs share a 
common structure, consisting of six distinct functional domains. The phosphotyrosyl tail 
segment [28] contains the conserved tyrosine residue involved in phosphorylation and 
dimerization. 
 
Shorter isoforms, distinct from the full length STAT (α-isoform) are 
generated by alternative mRNA splicing or post-translational proteolytic 
processing (β, γ, δ isoforms) [42]. 
1.5.2. Activation	  and	  inactivation	  	  
 
STAT3 is activated by numerous cytokines and growth factors (Table 1), 
as well by oncogenic proteins such as Src [43]. During activation, a single 
tyrosine residue located at the C-terminal end of the molecule (amino acid 
position 705) gets phosphorylated by receptor-associated tyrosine kinases 
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(TK) like JAKs, members of the Src family, or by activated growth factor 
receptors with intrinsic TK activity like EGF or PDGF receptor [27].  
Additionally, serine kinases including protein kinase C (PKC), mitogen-
activated protein kinases (MAPKs) or CDK5 [43], are able to 
phosphorylate a serine residue (amino acid 727) of STAT3. Function of 
serine phosphorylation seems to be controversial, where studies revealed 
the necessity for maximal transcriptional activation of STAT3 [44] but 
also the possible involvement in negative regulation [45]. Constitutive and 
exclusive phosphorylation of STAT3 on serine 727 showed to be a 
"hallmark" of chronic lymphocytic leukaemia (CLL), suggesting STAT3 as 
therapeutic target in this type of hematologic malignancy [46]. 
Besides tyrosine/serine phosphorylation, some other modifications also 
target STATs, such as acetylation, methylation, ubiquitination or 
sumoylation. STAT3 was found to be reversibly acetylated by histone 
acetyltransferase p300 at a single lysine residue (amino acid 685) which 
was shown to be critical for stable dimer formation [47]. 
The negative regulation of STAT3 activation is performed in several ways 
including inhibitory proteins, as the suppressor of cytokine signalling 
(SOCS), protein inhibitor of activated STAT (PIAS) and protein 
phosphatases, or through proteosomal degradation. 
The supressor of cytokine signalling (SOCS) protein family consist of eight 
members: SOCS-1, SOCS-2, SOCS-3, SOCS-4, SOCS-5, SOCS-6, SOCS-7 
and the cytokine-inducible SH2-domain containing protein CIS. The SOCS 
proteins with a central SH2-domain are able to bind to phosphotyrosine 
residues in cytokine receptors or in JAKs, supressing cytokine signalling 
at different steps by inhibiting JAKs activities (by direct binding), 
competing with STATs for receptor binding or targeting the signalling 
proteins for proteosomal degradation [48].  
The members of the PIAS family (PIAS1, PIAS2, PIAS3, PIAS4, PIASx 
and PIASy) are constitutively expressed nuclear proteins with SUMO-E3 
ligase activity [49]. PIAS3 is able to interact directly with the activated 
STAT3 molecules and specifically inhibit DNA binding and STAT3-
mediated gene expression [50].  
Negative regulation of STAT3 signalling can also be performed by 
dephosphorylation (remove of phosphate group) by protein phosphatases 
as TC-PTP (TC45) or SHP1 and SHP2 [51]. 
The ubiquitin dependent proteosomal pathway includes series of 
enzymatic reactions leading to the degradion of the target proteins such as 
regulatory molecules or transcription factors, including STAT3 [52]  
representing a regulation mode of protein stability [53].  
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1.5.3. STAT3	  and	  diseases	  
 
In the past years an increasing number of publications revealed STAT3 as 
a key player in chronic inflammation, autoimmune diseases or in different 
types of cancer progressions. The impaired function of STAT3 signalling is 
caused by genetic aberrations (mutations) or (in most cases) by the 
constitutive activation of  the transcription factor. 
In hyperimmunoglobulin-E syndrome (HIES, Job's disease), heterozygous 
mutations (missense or in-frame microdeletions) in the DNA-binding [54] 
and SH2-domains of STAT3 [55] result in the expression a full length but 
dysfunctional STAT3 molecules. These forms act as dominant negative 
resulting in ~75% inhibition of the active STAT3 homodimers. This 
inhibition effects Th17-cells function, resulting in immunodeficiency and 
susceptibility to infections [56]. 
In large granular lymphocytic leukaemia (LGL leukaemia), the SH2 and 
transactivation domain of STAT3 are frequently mutated (Figure 6) 
resulting in a hyperactivation of STAT3. This aberrant signalling 
underlies the pathogenesis of this disease [57]. 
Somatic mutations were also found in benign liver tumors (Figure 6 and 7) 
leading to so called inflammatory hepatocellular adenomas (IHCAs). The 
aminoacid changes affect the N-terminal, coiled-coil, linker and the SH2 
domain of the molecule, resulting in a mutant STAT3, which is 
constitutively active in a ligand independent manner [58]. 
 
 
 
 
 
Figure 6: The identified mutations found in different diseases, targeting 
structural domains of STAT3.  Most of the mutations were found in the SH2-domain, 
but were also identified in N-terminal, coiled-coil, DNA binding or linker domains. 
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STAT3’s role in cancer is a major topic in the biomedical research field. In 
contrast to the normal (transient) activation, STAT3 is frequently 
overactivated (persistent activation) in a variety of human solid tumors 
and blood malignancies including  breast, head and neck, lung, pancreatic 
and prostate cancers, as well as melanomas, multiple myelomas, 
leukaemias and lymphomas [59].  
This dysregulated activation brings STAT3 to the field as a central player 
in cancer cell growth, proliferation, survival,  angiogenesis, metastasis and 
invasion. Thus, STAT3 is emerging as a promising drug target for cancer 
treatment [60]. 
STAT3 also contributes in progression or remission in other diseases 
including rheumatoid arthritis (RA) [61], psoriasis [62], inflammatory 
bowel disease [63] or atherosclerosis [64]. 
 
 
 
 
 
Figure 7. Distribution of STAT3 somatic mutations identified in inflammatory 
hepatocellular adenomas (IHCAs) highlighted in the crystal structure of STAT3. 
(NTD: N-terminal domain, CCD: coiled-coil domain, DBD: DNA binding domain, LD: 
linker domain, SH2: SH2 domain. RCSB Protein Data Bank accession number is 1BG1, 
and 1BGF for STAT3 and N-terminal domain of STAT4 respectively, mutation sites and 
residues are highlighted in red). 
 
 
1.6. Dimers	  and	  higher	  molecular	  complexes	  in	  the	  STAT	  
family	  
 
In the early studies STATs were proposed in unstimulated state as latent 
monomeric proteins present in the cytosol of the cell, and dimerization 
occurs only upon phosphorylation after cytokine stimulation [39, 65].  
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In recent years several publications reported the existence of preformed 
(unstimulated) STAT dimers, tetramers (on DNA) but also associations of 
STATs in high molecular mass complexes, as statosomes, nuclear bodies 
or signalling endosomes. 
1.6.1. Preformed	  and	  activated	  dimers	  
 
It is a well established phenomenon, and demonstrated by various 
techniques that STATs are able to form stable dimers prior to stimulation 
[66-70], and have the capability of shuttling constitutively between 
cytoplasmic and nuclear compartments [71, 72]. 
Structurally the N-terminal domain seems to have the central role in the 
formation of unphosphorylated STAT dimers [73]. In context of STAT1 a 
model was proposed where the different STAT1 dimer conformations, 
performing antiparallel to parallel conversion, are involved in the 
activation-inactivation cycle [74, 75] (Figure 8 and Figure 9).  
 
 
 
 
 
Figure 8: Antiparallel and parallel dimer formations of STAT1. Antiparallel dimer 
formation is driven by N-terminal domain (NTD) homotypic interactions, and stabilized 
by interdomain interactions between coiled-coil (CCD) and DNA binding domains (DBD). 
Parallel dimers are stabilized by reciprocal interactions between phosphotyrosine motif 
and SH2 domain (adopted and modified from Ref. [75]). 
 
In this scenario the intermolecular interactions between the N-terminal 
domains are critical for the non activated dimer formation, and additional 
interactions between CCD and DNA-binding domain stabilize this 
antiparallel conformation, where the two C-terminal regions are localized 
in the opposite ends of the dimer. Following activation, the antiparallel 
dimer recruit the receptor, and after activation by tyrosine 
phosphorylation the dimer adopts a parallel conformation, stabilized 
through the „conventional“ reciprocal interaction between the 
phophotyrosine-motif and the SH2 domain. This connection orientates the 
dimer in a parallel formation and structurally allows the activated STAT1 
dimers to bind to specific DNA sequences.  
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After the release from the DNA, the newly established interaction 
between the N-terminal domains dissociates the phosphotyrosine-SH2 
interaction and stabilizes the dimer in an antiparallel conformation, 
facilitating the dephosphorylation procedure by exposing the phospho-
tyrosine residues to phosphatases [75]. 
 
 
 
 
 
Figure 9: STAT1 dephosphorylation model. Prior to stimulation STAT1 dimerize in 
an antiparallel orientation. Activation (through tyrosine phosphorylation) leads to the 
disruption of the antiparallel dimers and the molecules adopt a parallel orientation. The 
parallel dimers translocate to the nucleus and bind to specific DNA sequences. After the 
release from DNA the N-terminal domain driven reorientation and rotation of the dimer 
molecule leads to the re-formation of the antiparallel dimer, which exposes the tyrosine 
residues to phosphatases and facilitates the dephosphorylation procedure (adopted and 
modified from Ref. [75]). 
 
 
1.6.2. Tetramers	  and	  higher	  molecular	  complexes	  
 
The activated STAT dimers recognize consensus palindrom sequences on 
DNA: TTCN3-4GAA [76].  
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They can also bind cooperatively on promoters containing two or more 
binding sites, leading to tetramer formation, which is stabilized by 
interactions between N-terminal domains of the individual dimers [34].  
Stable tetramer formation on specific gene promoters is essential for 
maximal transcriptional activation [35], for cytokine responses and 
normal immune functions [77]. 
The first evidence that STAT proteins are also able to form high molecular 
weight complexes was found by gel filtration chromatography analysis in 
the cytosol fraction of liver cells. The protein assemblies were termed as 
statosome I (200-400 kDa) and statosome II (1-2 MDa) [78]. Similar large 
STAT oligomers were detected in living cells as slow diffusing components 
using fluorescence correlation spectroscopy (FCS) [79]. Statosomes 
possibly contain multiple STAT molecules associated with other proteins 
including scaffolding (caveolin-1) or heat shock proteins [80]. 
Special enrichment of STAT3 was found in the nuclear region in response 
to IL-6 stimulation, termed as nuclear bodies (Figure 10), possibly 
involved in active gene transcription or serving as reservoirs of the 
activated molecules [81]. 
 
 
 
 
Figure 10: (A) STAT3 nuclear body formation in response to stimulation in 
HeLa cells. HeLa cells stably expressing STAT3-eGFP induced with doxycycline (10 
ng/ml, 24 hours) and stimulated with IL-6 and soluble receptor (adopted from [82]). (B) 
STAT3 accumulation in nuclear and axonal region in embryonic stem (ES) cell 
differentiated neuron-like cells after cytokine addition. STAT3-YFP knock in ES 
cells (generous gift of Valeria Poli) derived neurons were stimulated with 100 ng/ml 
CNTF and analyzed with confocal microscopy. Bars, 10 µm. 
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Similar to nuclear bodies, accumulated STAT1 and STAT3 in nuclear 
particles were identified as paracrystals serving as dynamic reservoirs 
protecting STATs from dephosporylation [83]. 
The signalling endosome hypothesis describes a specialized way of signal 
transmission and is well established in long distance axonal 
communication [84]. After ligand binding the receptor complex is 
internalized by endocytosis. This complex recruits signalling molecules 
and associates with the microtubuli transport system forming a 
"signalling endosome" which is capable to initiate signalling. In the cell 
body, signalling endosomes may either initiate local signalling or move to 
the nucleus and start the transcriptional response [85]. The importance of 
signalling endosomes in JAK/STAT signal transduction still needs to be 
validated whether it is a common way of signal transmission or unique in 
specific cell types like neurons or dendritic cells. 
 
1.7. Single-­‐molecule	  spectroscopy	  and	  advanced	  microscopy	  
techniques	  
 
Single-molecule spectroscopy methods such as fluorescence correlation 
spectroscopy (FCS) allows the real-time analysis of biologically relevant 
molecules in solution or in living cells, giving access to molecular 
parameters like diffusion coefficients, hydrodynamic radii or  
concentrations [86]. 
Advanced fluorescence microscopy techniques including Förster resonance 
energy transfer (FRET) or various bleaching based methods (FRAP, FLIP) 
represent powerful tools to visualize and analyze complex dynamic events 
and interactions in cells, organelles or sub-organelle components in 
biological specimens [87]. 
 
1.7.1. Fluorescence	  correlation	  spectroscopy	  (FCS)	  
 
Fluorescence correlation spectroscopy (FCS) technique was developed in 
the early 1970s as a „miniaturized“  version of dynamic light scattering. In 
the first application, FCS was used to study the reversible binding 
reaction of ethidium bromide (EtBr) to DNA [88].  
In general, FCS analyzes the fluctuations of fluorescently labelled 
molecules, which arise from the diffusion through a subfemtoliter 
detection volume illuminated by a focused laser beam (Figure 11). 
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Figure 11: Basic features of fluorescence correlation spectroscopy (FCS). The 
exciting laser beam is directed to the objective with the use of a dichroic mirror and 
focused on the sample generating a very small detection volume. The diffusion of the 
fluorescently labelled particles in and out from the excitation volume is detected in time 
as fluctuations in the fluorescence signal. The fluorescence light collected by the 
objective, passes through the dichroic mirror, emission filter and is focused on a detector 
with single photon sentitivity (APD: avalanche photodiode). 
 
 
The fluctuation traces are recorded in time and quantified by 
autocorrelation analysis (Figure 12). The autocorrelation function (ACF) 
describes the variance of fluorescence fluctuations and provides a measure 
for the self-similarity of the signal as a function of time.  
The mathematical analysis of the ACF provide quantitative information 
about the mobility (diffusion coefficient, D) or the concentration (C) of the 
investigated molecule [89].  
During the past years new variations of FCS were established: scanning 
FCS (sFCS), the two color fluorescence cross correlation spectroscopy 
(FCCS) [90] or two focus FCS (2f-FCS) [91]. 
sFCS is a modified fluorescence spectroscopy technique, where the 
detection volume is moved across the sample in a defined way and 
circumvents some detection problems (slower dynamics, photobleaching) 
of the standard FCS and makes the technique more applicable in 
biological systems [92]. 
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Figure 12. Fluorescence correlation spectroscopy analyzes the fluctuations of 
the fluorescence signal. The fluorescencently labelled particles move in and out from 
the detection volume (due to the Brownian motion) which causes the fluctuations in the 
fluorescence intensity. The intensity changes are followed and analyzed over time (F: 
fluorescence intensity, τ: lag time, t: time). The fluctuations are quantified by autocorrelating 
the recorded signals (observe the self similarity of the fluorescence signal in a time 
intervals). The experimental autocorrelation function (ACF) is fitted with a mathematical 
model to extract information such as molecular mobility or concentation (N: number of 
particles, τ D: diffusion time). 
 
 
The two color version of FCS, the fluorescence cross correlation 
spectroscopy (FCCS) in therory has been suggested in 1994 [93] and 
experimentally verified in 1997 [94]. The FCCS analyzes the movement of 
two differently (with spectrally distinct fluorophores) labelled particles to 
gain information about their mobilities or interactions. The technique is 
well suited to study direct protein-protein interactions, enzyme kinetics or 
dynamic colocalizations in biological samples [95]. 
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The dual-focus or two-focus fluorescence correlation spectroscopy (2f-FCS) 
is an improved FCS-setup, which introduces an external ruler (two 
laterally shifted but overlaping laser foci with a fixed and well known 
distance) in the system and measures the absolute values of diffusion 
coefficients with high precision and accuracy, without the need of further 
referencing [91]. 
In recent years the FCS became a widely used technique to follow and 
study dynamic processes in biological systems. In our study we applied the 
2f-FCS to analyze the diffusion properties and complex formation of the 
transcription factor STAT3.  
 
1.7.2. Förster	  resonance	  energy	  transfer	  (FRET)	  
 
The resonance energy transfer initially was investigated by Jean Perrin at 
the beginning of the 20th century, and the correct theoretical basis was 
described by Theodor Förster in 1948, as a process in which energy is 
transferred in a nonradiative manner via long-range dipol-dipol coupling 
from a donor fluorophore (in electronic excited state) to an acceptor 
chromophore [96] (Figure 13). 
 
 
 
 
 
Figure 13: Basic principles of Förster resonance energy transfer (FRET).  When 
the donor (green) and acceptor (red) fluoorophore are distant from each other, as a 
consequence of donor excitation, donor fluorescence will detectable. If the two 
fluorophores are located in close proximity, energy can transfer non-radiatively from the 
donor to the acceptor fluorophore (FRET) and can be detected as incrased acceptor 
fluorescence emission. Donor emission is reduced as a consequence of the energy transfer. 
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FRET is an acronym from Förster resonance energy transfer or from the 
oftenly used fluorescence resonance energy transfer, where fluorescence 
refers to the use of fluorescent donor and acceptor chromophores (energy 
is not transferred through fluorescence). 
Energy transfer occurs between small distances (1-10 nm) and allows the 
detection of direct molecular interactions beyond the limit of conventional 
light microscopes (improved spatial resolution). The transfer rate is 
dependent on the sixth power of distance, thus FRET can be used as 
„spectroscopic ruler“ to reveal proximity relationships in biological 
macromolecules [97].  
FRET can be performed inter- (donor and acceptor localized at different 
molecules) or intramolecularly (donor and acceptor are at the same 
molecule) and is a widely used technique in molecular biology to study 
direct interactions or conformational changes. 
The energy transfer can be visualized in several ways and using different 
approaches, but in general three oftenly used strategies can be 
distinguished: acceptor photobleaching (APB), sensitized emission (SE) 
and  fluorescence lifetime imaging (FLIM). 
Sensitized emission (SE), is a quantitative imaging approach [98], in 
which only the donor fluorophore is excited, and as a consequence of FRET 
the acceptor fluorophore becomes excited instead, which can be detected as 
increased acceptor emission.  
In fluorescence lifetime imaging (FLIM), the donor fluorescence quenching 
is detected, and can be determined as decrease of fluorescence decay time 
of the donor fluorophore in the presence of FRET [99]. 
In acceptor photobleaching (APB) technique, the acceptor fluorophore is 
selectively bleached and the donor fluorescence intensity is analyzed over 
time. If FRET occurs the disruption of the energy transfer (bleaching) 
leads to an increased donor emission as the consequence of losing the 
quenching effect  
In our work we used the APB to follow the dimerization and structural 
changes of STAT3 prior and upon activation. 
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1.8. Hypothesis	  and	  aims	  
 
The transcription factor STAT3 plays crucial roles in many biological 
processes and the constitutively activation occurs in various human 
tumors. This aberrant activation validates STAT3 as a promising cancer 
drug target and intensive research focuses on the generation of specific 
inhibitors against the protein.  
 
The design of inhibitor molecules undermining the malignant phenotype 
could be performed in different ways and directly effect different 
interfaces or domains of the STAT3 molecule, as SH2 domain 
(dimerization inhibitors), DNA-binding domain, or inhibitors against the 
N-terminal domain. Indirect targeting could be achieved by inhibition of 
upstream components of the pathway (tyrosine phosphorylation 
inhibitors) [100]. 
 
The dimerization of  STAT3 is not restricted to „activation modus“, but 
also occurs in latent state, in absence of tyrosine phosphorylation, as it is 
confirmed by various techniques like FRET [70] or BRET[69]. However 
the structural requirement of preformed dimers and the possible functions 
in context of STAT3 signalling is not known.  
 
In our research we focused on the dimerization and complex formation of 
STAT3 prior and after stimulation. For the correct visualization we used 
fluorescence based microscopy techniques as two-focus fluorescence 
correlation spectroscopy (2f-FCS) or Förster resonance energy transfer 
(FRET) method. 
 
For this purpose we focused on the following points: 
 
• Generate fluorescently labelled STAT3 constructs for 2f-FCS and 
donor/acceptor pairs for FRET mesurements. 
• Establish the sample preparation and micrsocopy setup for 
detecting molecular dynamics of STAT3 with two-focus fluorescence 
correlation spectroscopy. 
• Optimize the imaging setup and analysis for the correct 
interpretation and visualization of the FRET signal between 
fluorescently labelled STAT3 molecules. 
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Given the previous findings in context of STAT3 dimerization, our gain 
was to analyze the structural requirement of the unphosphorylated 
STAT3 dimers, more specifically: 
 
• Examine which interdomain interaction stabilize the preformed 
dimer (homotypic or heterotypic interdomain interaction) 
• Identify which domain(s), and which amino acid residue(s) are 
critical in the dimerization of the non-activated STAT3 molecules.  
 
While investigating the structural background of dimerization, our goals 
were: 
 
• Visualize the conversion of STAT3 homodimers from preformed 
„non activated“  state to „activated“  form. 
• Functionally analyze and identify the possible roles of preformed 
dimers in the STAT3 activation cycle. 
 
Focusing on the N-terminal domain of STAT3 we were interested in: 
 
• Interdomain interactions of N-terminal fragment with other 
structural domains of STAT3. 
 
• N-terminal homotypic interactions in the stabilization of STAT3 
tetramers on specific gene promoter regions. 
 
• Structural requirements of STAT3 tetramerization. 
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2. Materials	  and	  methods	  
 
2.1.	  Materials	  
 
2.1.1.	  Chemicals	  and	  reagents	  
 
All chemicals and reagents were prepared according to pro analysi quality 
standards. All water solutions were prepared in double destilled water. 
 
2.1.2.	  Cytokines	  and	  receptors	  
 
Recombinant human IL-6 (1400 U/µl) and soluble IL-6 receptor (sR) were 
prepared as described in [101] and [102]. 
 
2.1.3.	  Antibodies	  
 
 
 
2.1.4.	  Plasmids	  
 
All plasmid constructs were generated with the use of pcDNA5/FRT/TO 
expression vector (Invitrogen, USA).  
The vector contains a hybrid human cytomegalovirus CMV/TetO2 
promoter for high-level and tetracycline-regulated expression, a multiple 
cloning site (MCS), ampicillin resistance gene, FLP Recombination Target 
(FRT) site for Flp recombinase-mediated integration of the vector and 
hygromycin resistance for the selection of stable cell lines. 
Antibody	   Recognized	  site	   Source	   Derived	  from	   Company	  
Anti-STAT3 
(C20) 
STAT3 C-teminal 
region 
polyclonal Rabbit Santa Cruz, 
USA 
Anti-STAT3 
(H190) 
STAT3 N-terminal 
region 
polyclonal Rabbit Santa Cruz, 
USA 
Anti-pSTAT3 
(pY705) 
STAT3 
phosphotyrosine 
705 motive 
polyclonal Rabbit Cell Signaling, 
USA 
Anti-GAPDH 
(6C5) 
GAPDH monoclonal Mouse Santa Cruz, 
USA 
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Table 2. Summary of plasmid constructs used in this thesis. 
 
Name Vector Comments 
eGFP Clontech, USA eGFP encoding plasmid 
pSNAP-Cox8A SNAP-tag control plasmid 
(New England Biolabs, 
USA) 
cytochrome C oxidase 
subunit 8-2 fused to the N-
terminal end of SNAP-tag 
SNAP-eGFP pcDNA5/FRT/TO SNAP tag fused to eGFP with 
a TGDDDDKA linker 
(positive FRET control) 
eGFP-STAT3 pcDNA5/FRT/TO  eGFP fused to the N-terminal 
end of STAT3α 
STAT3-eGFP pcDNA5/FRT/TO  eGFP fused to the C-terminal 
end of  STAT3α 
SNAP-STAT3 pcDNA5/FRT/TO  SNAP-tag fused to the N-
terminal end of  STAT3α 
STAT3-SNAP 
 
pcDNA5/FRT/TO  SNAP-tag fused to the C-
terminal end of  STAT3α 
ΔNTD-STAT3-eGFP pcDNA5/FRT/TO  N-terminal (aa 1-125) deleted  
STAT3α, eGFP fused to the C-
terminal end of STAT3 
ΔTAD-STAT3-SNAP pcDNA5/FRT/TO  C-terminal (aa 710-770) 
truncated  STAT3α, SNAP-
tag fused to the C-terminal of 
STAT3 
SNAP-NTD pcDNA5/FRT/TO  SNAP-tag fused to the N-
terminal domain (aa 1-125) of  
STAT3α 
SNAP-NTD(L78R) pcDNA5/FRT/TO  SNAP-tag fused to the N-
terminal domain (aa 1-125) of  
STAT3α, where L78 residue is 
mutated 
SNAP-STAT3(L78R) pcDNA5/FRT/TO N-terminal residue L78 
mutated, SNAP-tag fused to 
the N-terminal end of 
STAT3α 
STAT3(L78R)-SNAP pcDNA5/FRT/TO  N-terminal residue L78 
mutated, SNAP-tag fused to 
the C-terminal end of STAT3α 
eGFP-STAT3-SNAP pcDNA5/FRT/TO  eGFP fused to the N-
terminal, SNAP-tag to the C-
terminal of  STAT3α 
eGFP-STAT3(R609Q)-
SNAP 
pcDNA5/FRT/TO  eGFP fused to the N-
terminal, SNAP-tag to the C-
terminal of  STAT3α, where 
R609 residue is mutated 
   
 
24 
 
2.2.	  Cell	  lines	  and	  culture	  techniques	  
 
2.2.1.	  Prokaryotic	  cells	  and	  cultivation	  
 
For molecular cloning the following E.coli bacterium strains were used: 
 
JM83: F- ara Δ(lac-proAB) rpsL (Strr) [φ80 d lacΔ (lacZ)M15] thi 
DH5alpha: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ– 
 
XL-10: endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 Tn10(TetR Amy 
CmR)] 
 
XL1-blue: endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 
proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+) 
 
Recombinant E. coli cells were cultivated in LB-medium with ampicillin 
(100mg/l). For long-term storage, the bacterial cells were stored at -80°C 
with 20% glycerin. 
 
 
LB-(Luria-Bertani) medium: 5 g/L  NaCl  
 
     5 g/L  yeast extract (Difco, USA)  
 
     10 g/L  Trypton (Difco, USA)   
 
	  
2.2.2.	  Transformation	  of	  competent	  bacteria	  
 
Plasmid DNA (1-5 ng) or 10-20 µl from the ligation solution was mixed  
with 100 µl competent bacteria and incubated for 30 minutes on ice. 
Incubation was followed by a heat shock at 42°C for 90 seconds and with 
another incubation step on ice for 120 seconds. The mixture was plated on 
a selective (ampicillin, 100 mg/l) LB-agar plate, and incubated overnight 
at 37°C. Clones were screened and selected for further analysis. 
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2.2.3.	  Eukaryotic	  cells	  and	  cultivation	  
 
The eukaryotic cell lines (Cos-7, HeLa and HepG2) were cultivated in the 
indicated cell culture media, supplemented with fetal calf serum (FCS) 
and penicillin/streptomycin. Cells were grown at 37°C in a humidified 
atmosphere containing 5% CO2 and passed by trypsinization. First, cells 
were washed with phosphate buffered saline (PBS), followed by the 
addition of trypsin/EDTA and an incubation step for 5 minutes at 37°C. 
Cells were detached with the addition of growth medium followed by 
gentle pipette action and seeded in new culture flask with a delution from 
1:5 to 1:10. Long term storage was carried out in liquid nitrogen at -150°C 
with the addition of 10% dimethyl sulfoxide (DMSO). 	  
Cos-7: african green monkey kidney fibroblast-like cell line (A.T.C.C., 
USA), cultivated in phenol red free DMEM-medium (Gibco, Germany), 
supplemented with 10% FCS and 1% penicillin/streptomycin. 	  
HeLa : human cervix adenocarcinoma cell line (A.T.C.C., USA), cultivated 
in phenol red free DMEM-medium (Gibco, Germany), supplemented with 
10% FCS and 1% penicillin/streptomycin. 
 
HepG2: human liver hepatocellular carcinoma cell line (A.T.C.C., USA), 
cultivated in DMEM/F12-Medium (Gibco, Germany), supplemented with 
10% FCS and 1% penicillin/streptomycin. 
 
 
PBS (phosphate buffered saline): 200 mM  NaCl 
 2,5 mM  KCl 
 8 mM  Na2HPO4 
 1,5 mM  KH2PO4 
   pH 7.4 
	  
2.2.4.	  Transfection	  of	  eukaryotic	  cells	  
 
Transfection was performed transiently, when cells reached a density of 
60-80% confluence, by using transfection reagent TransIT-LT1 (Mirus Bio 
LLC, USA), and OPTIMEM (Gibco, Germany) as serum free medium. 
Conditions and protocols used according to the manufacturer´s 
instructions. 
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2.3.	  Molecular	  biology	  techniques	  
 
2.3.1.	  Polymerase	  chain	  reaction	  (PCR)	  
 
Polymerase chain reaction is a widely used technique in molecular biology 
to specifically amplify single DNA sequences. The name of the method is 
derived from the DNA polymerase, which is the key component of the 
DNA replication procedure.  
Components required for a PCR reaction are: DNA template (DNA 
sequence to be copied), primers (single stranded oligonucleotides, sense 
and antisense), heat stable DNA polymerase (Phusion HF, New England 
Biolabs, USA), dNTPs (deoxyribonucleotide triphosphates, building blocks 
for DNA) and buffer solution (generating the optimal conditions for the 
reaction). 
The three basic steps of a PCR reaction are: denaturation, annealing and 
extension step, which are repeated 25-35 times, taking place at different 
temperatures. In the end of the reaction millions of copies generated from 
the target DNA sequence. 
 
 
 
PCR reaction mixture:  5 ng   Template DNA 
     500 pmol  Sense primer 
     500 pmol  Antisense primer 
     1 mM   dNTP mix 
     1U   DNA polymerase 
     10 µl   Reaction buffer 
 
      add H2O to 50 µl 
 
 
PCR reaction cycles: 
 
     Initial denaturation    98°C   (30s) 
     Denaturation     94°C   (5-10s) 
     Annealing       48°C   (10-30s)      
     Extension       72°C   (15-30s)  
     Final extension      72°C (5-10min)  
  
      
 
25-35 cycles 
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2.3.2.	  Isolation	  of	  plasmid	  DNA	  
 
Plasmid MiniPrep: 
 
A single bacterial colony was picked from the plate, and inoculated in 3 ml 
ampicillin (100 mg/l) containing LB-medium. Incubated overnight at 37°C, 
using vigorous shaking. In the next step, the bacterial cells were 
harvested by centrifugation (6000 rpm, 10 minutes, at room temperature), 
the pellet was resuspended and plasmid DNA extraction and purification 
performed using QIAprep-Miniprep-Kit (Qiagen, Germany) according to 
the manufacturer´s protocol. 
 
Plasmid MaxiPrep: 
 
250 ml ampicillin  (100 mg/l) containing LB-medium was inoculated with 
100 µl bacterial suspension, and incubated overnight at 37°C with 
vigorous shaking. Next, bacterial cells were harvested by centrifugation 
(6000 rpm, 15 minutes, at 4°C), the pellet was resuspended and plasmid 
DNA extraction and purification was performed using QIAprep-Maxiprep-
Kit or with HiSpeed Maxy Kit (Qiagen, Germany) according to the 
manufacturer´s protocol. 
 
 
2.3.3.	  Determination	  of	  the	  plasmid	  DNA	  concentration	  
 
Plasmid DNA concentration was calculated based on the value of OD260nm 
(optical density at 260 nm) using UV-spectrophotometer (NanoDrop, 
ThermoScientific, USA). The ratio of OD 260 and OD 280 nm indicates the 
purity of the DNA (for pure DNA: OD260nm / OD280nm: 1.8-2.0). 
 
 
2.3.4.	  Digestion	  of	  DNA	  using	  restriction	  endonucleases	  
 
DNA digestion with restriction endonucleases was performed according to 
the manufacturer´s protocol. In analytical digestion 0.5-1 µg, for 
preparative 2-5 µg DNA was used. In case of digestion with two 
endonucleases, the selected buffer ensured at least 75% efficiency for both 
enzymes. After digestion, DNA-fragments were analyzed with agarose gel 
electrophoresis. 
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2.3.5.	  Agarose	  gel	  electrophoresis	  
 
Gel electrophoresis is used in molecular biology to separate a mixed 
population of DNA molecules from 50 bp to several kilobases. The method 
is based on the applicaton of an electric field to move the negatively 
charged molecules through an agarose matrix. Larger DNA fragments 
migrate more slowly and move smaller distances than the shorter ones, 
therefore DNA fragments of different size can be seperated from each 
other.	  
DNA samples were mixed with 1/10 volume of 10 × loading buffer, loaded 
on a 1% agarose gel (Seakem-LE-Agarose, Biozym, Germany in TAE-
Puffer) and separated by using an electric field of 5V/cm2.  
DNA was visualized with UV-light and the size of the DNA-fragments was 
estimated using 1 Kb DNA ladder (Invitrogen, Germany). 
 
 
10 × DNA loading buffer:   25%   Ficoll  
      0.4%   Xylencyanol blue 
      0.4%   Bromophenol blue 
 
 
1 × TAE:     40 mM  Tris base 
      20 mM  Acetic acid 
      1 mM  EDTA 
 
 
2.3.6.	  Isolation	  of	  DNA	  fragments	  
 
After agarose gel electrophoresis, the appropriate DNA bands were 
excised from the agarose gel. Elution and purification was performed  
using QIAquick-Gel-Extraction-Kit (Quiagen, Germany) according to the 
to the manufacturer´s protocol. 
 
2.3.7.	  Ligation	  of	  DNA	  fragments	  
 
Purified, double-stranded DNA fragments were ligated to the linearized 
plasmid (molar ratio 3:1) with T4 DNA ligase (in 10 × ligation buffer) and 
incubated at room temperature for 2-4 hours. Following the incubation 
step, ligated DNA samples were transformed into competent E. coli cells. 
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2.3.8.	  DNA	  sequencing	  
 
DNA sequencing analysis was performed by MWG Biotech AG 
(Martinsried, Germany) using the appropriate sequencing primers. 
 
2.3.9.	  Site	  directed	  mutagenesis 
 
Site directed mutagenesis was performed by using QuickChange 
mutagenesis kit (Agilent Technologies, USA) to introduce mutations into 
STAT3.  
A pair of primers was used to generate L78R mutation into the wild type 
STAT3. They are: 5-‘CAAGAGTCCAATGTCCGCTATCAGCACAACCTTC-
3‘ and 5‘-GAAGGTTGTGCTGATAGCGGACATTGGACTCTTG-3‘. 
 
2.3.10.	  Reporter	  gene	  assay	  
 
A reporter gene assay was used to study the induction of the α2-
macroglobulin  promoter by STAT3.  
HepG2 cells were grown in six-well plates and transfection was performed 
with 1 µg β-galactosidase expression vector (pCR3lacZ, Pharmacia, 
Sweden), 300 ng of luciferase reporter construct (α2-macroglobulin) and 
the indicated plasmid constructs using TransIT-LT1 transfection reagent 
(Mirus Bio LLC, USA) according to the manufacturer´s instructions. 
After 24 hours cells were stimulated for 4 hours, lysed and incubated on 
ice for 30 minutes. Following incubation the samples were centrifugated 
(14,000 rpm, 10 minutes, at 4°C), supernatants were collected and used for 
the further experiments. β-Gal measurements were performed with 100 µl 
cell extracts and 100 µl ortho-Nitrophenyl-β-galactoside (ONPG) in 500 µl 
β-Gal buffer. Samples were incubated at 37°C, and the reaction was 
stopped with the addition of 500 µl Na2CO3. Absorbance was measured at 
420 nm.  Luciferase assays were performed using a luciferase assay kit 
(Promega, Germany) and values were normalized to transfection 
efficiencies derived from β-Gal expression. 
 
β-galactosidase buffer:   60 mM  Na2HPO4 
      40 mM NaH2HPO4 
      1   mM KCl 
      1   mM MgCl2 
      3.86 ml/l β-Mercaptoethanol 
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2.4.	  Protein	  analysis	  and	  immunological	  methods	  
 
2.4.1.	  Protein	  extraction	  
 
All steps of protein extraction were performed at 4°C with pre-cooled 
buffers. Cells were washed with PBS, collected and incubated with 150 µl 
RIPA lysis buffer for 30 minutes on ice. After vortexing, the sample was 
centrifuged (14,000 rpm, 10 minutes, at 4°C), supernatants were collected 
and stored for further analysis at -20°C. 
 
 
RIPA-Lysisbuffer:          50  mM    Tris/HCl, pH 7.4 
 150 mM NaCl 
 1 mM EDTA 
 0.5 % Nonidet P-40 
 1 mM NaF 
 15 % Glycerol 
 20 mM β-Glycerolphosphate 
 
 
 
Protease inhibitors were added to the lysis buffer prior to use. 
 
 
 
Protease inhibitor: 1 mM Na-Vanadate 
 0,5 mM EDTA 
 0,25 mM PMSF 
 5µg/ml Aprotinin 
 1µg/ml Leupeptin 
  
 
2.4.2.	  Determination	  of	  protein	  concentration	  
 
Protein concentrations were determined using Bradford assay. The 
method is based on the detection of the absorbance shift (465 nm to 595 
nm) from the Coomassie Brilliant Blue G-250 dye upon protein binding.  
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The OD595nm is directly proportional to the concentration of the proteins. 
For measuring the protein concentrations after extraction, 5 µl protein 
lysate was used with 200 µl Bradford reagent (BioRad, Germany) and 
ddH2O in a total volume of 1000 µl. The protein samples were incubated 
for 5 minutes at room temperature and absorbance was measured at 595 
nm. 
 
2.4.3.	  SDS	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  
 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) is 
a common method for protein separation based on their electrophoretic 
mobility in denaturated conditions. Protein extracts (containing same 
amount of proteins: 20 µg) were denaturated by heating at 95°C for 5 
minutes in Laemmli-buffer (4×) and centrifugated at 4°C (13,200 rpm, 30 
seconds). After centrifugation, the samples were loaded on SDS gel and 
electrophoresis was performed with 35 mA at room temperature. 
 
 
SDS-running puffer: 1,5 % Tris-Base, pH 8.3 
  7,2 % Glycine 
  0,5 % SDS 
 
 
4 × Laemmli-buffer: 40 % Glycerol 
  8 % SDS 
  250 mM Tris/HCl, pH 6.8 
  0,4 % Bromphenolblue 
    20 % β-Mercaptoethanol 
     
 
Separation gel: 10 % Acrylamide 
  375 mM Tris/HCl, pH 8.8 
  0,1 % SDS 
  0,02 % TEMED 
 0,1 % APS 
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Stacking gel: 5 % Acrylamide 
  125 mM Tris/HCl, pH 6.8 
  0,1 % SDS 
  0,02 % TEMED 
  0,1 % APS 
 
2.4.4.	  Western	  blot	  and	  immunodetection	  
 
To detect protein of interest, the separated protein samples were 
electrically transferred to a polyvinilydene (PVDF) membrane (PALL, 
Germany) using the Western blot technique.  
 
 
Anode buffer I:    300 mM Tris-Base, pH 10.4 
 
Anode buffer II:    25 mM Tris-Base, pH 10.4 
 
Cathode buffer:    400 mM 6-Aminohexanoic acid 
 
 
 
After blotting, the PVDF membrane was blocked for 45 minutes with 10% 
bovine serum albumin (BSA) to prevent the non specific binding of 
primary/secondary antibodies. After blocking, the membrane was washed 
in TBS-N buffer for 5 minutes at room temperature. Following washing 
step, the primary antibody was deluted in TBS-N (1:1000) and the 
membrane incubated over night at 4°C.  
Next day, primary antibody was removed and the membrane was washed 
three times for 10 minutes with TBS-N, followed by the addition of 
secondary antibody (1:2000 delution in TBS-N) and incubation for 1-1.5 
hours. After incubation, the membrane was washed with TBS-N (three 
times, 10 minutes) and proteins were detected using ECL-detection 
system (Millipore, USA) with a chemiluminescence detektor LAS-4000 
(FujiFilm, Japan).  
For protein counterstaining, the PVDF membrane was incubated with 
stripping buffer, containing freshly added β-mercaptoethanol and 
incubated at 70°C for 25 minutes.  Stripping was followed by blocking with 
10% BSA, washing steps with TBS-N and addition of the primary antibody 
of interest and the previously described process was repeated. 
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TBS-N buffer:    20 mM Tris/HCl, pH 7.4 
      137 mM NaCl 
      0.1 %  Nonidet P-40 
 
Stripping-buffer:    100 ml 20% SDS 
      62.5 mM Tris/HCl, pH 6.7 
          
2.4.5.	  Blue	  native	  PAGE	  
 
Proteins can be separated from each other in non-denaturating conditions 
using the blue native page technique [103].  
Electrophoresis was performed with 30 µg protein, over night at 4°C with 
40V. Fluorescence detection of STAT3-YFP was performed by using a 
fluorescence scanner (Typhoon, GE Healthcare, UK). The probe was 
excited with 488 nm laser line and the emission detected using 515-555 
nm band filter setting.  
 
                                            
5 × Probe buffer:                             100 mM ε-Aminocapronic acid 
                                         50 % Glycerol 
                                                         1 % Coomassie Brilliant-Blue G250 
 
Cathode buffer:                               50 mM Tricine 
                                         15 mM BisTris, pH 7 
                                                         0.002 % CoomassieBrilliant-BlueG 250 
 
 
Anode buffer:                                  50 mM BisTris/HCl, pH 7 
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2.5.	  Fluorescence	  techniques	  
 
2.5.1.	  Confocal	  laser	  scanning	  microscopy	  (CLSM)	  
 
The conventional light microscopes are well established devices to observe 
cell structures and compartments illuminated by visible light source. The 
confocal laser scanning microscopy (CLSM) uses a laser beam for 
illumination and combines the high-resolution optical imaging with 
improved depth selectivity [104]. The original technique was invented by 
Marvin Minsky in 1957 [105]. 
The key feature of CLSM is the acquisition of well focused images from 
various depth in the sample (optical sectioning) with a pinhole in front of 
the detector, which shields the emitted out of focus light [87] (Figure 14). 
 
 
 
 
 
Figure 14: Schematic illustration of the confocal ligth path with respresentative 
image. The laser beam is focused on the sample and the fluorescence light is re-collected 
by the objective lens. The collected light passes through the dichroic mirror, emission 
filter and confocal pinhole to the detector (PMT or APD). The represenative images are 
ES cell differentiated neuron-like cells labelled with antibody against an early neuronal 
marker (MAP2A) and visualized by confocal imaging (DIC: differential interference 
contrast image). Bars, 10 µm. 
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2.5.2.	  Potein	  labelling	  with	  genetically	  encoded	  fluorophores	  
 
The term „fluorescence” was first coined by George G. Stokes in 1852 to 
describe the phenomenon when a mineral fluorite emits photons in the 
visible spectrum upon irradiation with ultraviolet light [106].  
The main step for applying fluorescence in biological systems was the 
developement of genetically encoded fluorescent proteins (FPs). Specific  
labelling of biological molecules with fluorescent tags gives a very 
powerful tool to specifically follow subcellular localization or dynamics in 
living cells.   
 
 
 
 
 
Figure 15: Structural background of green fluorescent protein (GFP). GFP 
adopts a 11-stranded β-barrell structure associated with an α-helix. The chromophore is 
located in the deep centre of the molecule and composed of a conjugated ring structure 
derived from amino acids Ser65, Tyr66 and Gly67 (RCSB Protein Data Bank accession 
numbers for GFP is 1GFL). 
 
 
A widely used member of the FP-family is the green fluorescence protein 
(GFP). The original protein was firstly isolated by Osamu Shimomura 
from the jellyfish Aequorea victoria in 1960s [107]. 30 years later, Martin 
Chalfie presented GFP as a potential marker of gene expression [108]. The 
improvement of the original fluorophore and also the generation of new 
variants for biological research by protein engineering was pioneered by 
Roger Tsien [109].  
For the discovery and development of Aequorea victoria GFP as a widely 
applied tool for cell biology Shimomura, Chalfie and Tsien were awarded 
the Nobel Prize in chemistry in 2008.  
The wild type form of GFP which was found in A. victoria is a 27 kDa 
protein, which following translation folds into a 11-stranded β-barrell 
structure with an α-helix, which runs through the centre of the barrell.  
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The chromophore (4-p-hydroxy-benzylidene-5-imidazolinone) is formed 
deep in the hydrophobic core and composed of a conjugated ring structure 
derived from amino acids Ser65-Tyr66-Gly67 [110, 111] (Figure 15).  
In our work we used the enhanced version of GFP (eGFP), carrying the 
S65T mutation, leading to improved spectral properties (brightness, 
photostability) of the fluorophore [109] and a F64L substitution, which 
results in a better folding efficiency at 37°C [112]. 
 
2.5.3.	  Chemical	  labelling	  of	  proteins	  
 
Besides the conventional method of protein labeling with genetically 
encoded fluorophores, there are other possibilities of specifically and 
covalently “tagging” the protein of interest with a label of choice using 
chemical modifications. So called, tag-based protein labeling methods can 
be grouped into three families: self labeling tags (tetracysteine tag, 
tetraserine tag), self labeling proteins (Halotag, SNAP-tag, CLIP-tag) and 
enzyme mediated labeling of tags (PPTase and biotin ligase) [113].  
In our work we used a self labeling protein tag family member, the SNAP-
tag, to generate fluorescently labeled protein samples for our investigations.  
 
 
 
 
Figure 16: Structural organization of the SNAP-tag. The SNAP-tag is an 
engineered version of O6-alkylguanine-DNA-alkyltransferase (AGT). The original form is 
a repair protein which plays a role in the defense against O6-alkylation of guanine in 
DNA by alkylating agents. This repair is catalyzed by AGT, transferring the alkyl group 
to one of its own cysteine residues [114] (RCSB Protein Data Bank accession numbers for 
SNAP-tag is 3KZZ). 
 
 
The SNAP-tag (Figure 16) is a 20 kDa protein, which is an engineered 
version of the DNA repair protein, O6-alkylguanine-DNA-alkyltransferase 
(AGT)[115]. After subcloning and expression of the SNAP fusion protein 
construct, in the labelling reaction the modified AGT forms a covalent 
thioether bond specifically reacting with O6-benzylguanine (BG) derivates 
carrying the fluorophore, resulting in covalently and specifically labeled 
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protein [116] (Figure 17). Using cell permeable fluorescent substrates, 
labeling can be also performed in living cells, making the SNAP-tag 
technology a very useful method in different fluorescence based 
microscopy applications as localizable calcium indicators, photoswitchable 
probes for super resolution microscopy techniques or FRET-based 
fluorescent sensors [117].  
 
 
 
Figure 17: The SNAP-tag labelling mechanism. In the labelling reaction the SNAP-
tag forms a covalent thioether bond with O6-benzylguanine (BG) derivates carrying the 
fluorophore, resulting in covalently labelled protein of interest (modified from Ref. [117]). 
 
2.5.4.	  SNAP-­‐tag	  labelling	  procedure	  
 
The labelling of the SNAP-tag fusion proteins was performed using SNAP-
Cell TMRstar substrate (New England Biolabs, USA). Labelling procedure 
was carried out according to  the manufacturer´s protocol. 
 
2.5.5.	  Imaging	  of	  fixed	  probes	  
 
Cells were seeded and grown on Lab Tek four well chamber slides (Nunc, 
Thermo Fisher Scientific, USA) in phenol red free medium. Transfection 
was  performed as described previously.  
After removing the medium, cells were washed two times in PBS++. 
Fixation was performed by addition of 200 µl methanol to the cells, 
followed by incubation in the dark, for 20 minutes at room temperature.  
After incubation, the cells were washed once with PBS++ and quenched 
with 50mM NH4Cl (deluted in PBS++) for 5 minutes. 
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Coverslips were mounted with Immu-Mount (Thermo Fisher Scientific, 
USA) and the samples kept in the dark until further investigation. 
 
 
   PBS++ :   1 mM  MgCl2  
       0.1 mM CaCl2  
       in  PBS  
  
 
2.5.6.	  Imaging	  of	  living	  cells	  
 
For live cell imaging, cells were plated on 35 mm glass bottom dishes 
(Ibidi, Germany) in phenol red free medium 48 hours before the 
experiment and transfected as described previously. Cells were imaged at 
37°C and 5% CO2  in the cell incubator a of Zeiss LSM 710 microscope 
(Carl Zeiss, Germany) 
For living cell FRET experiments, cells were plated and seeded on eight 
well µ-Slides (Ibidi, Germany) and analyzed as described before. 
 
2.5.7.	  Dual	  focus	  fluorescence	  correlation	  spectroscopy	  (2f-­‐FCS)	  
 
The basic concept of 2f-FCS is the use of two laterally shifted and 
overlapping foci (detection volume) with a fixed and well known distance, 
serving as an external ruler in the experiment.  
The analysis of the autocorrelation functions (ACFs) from each foci, and 
the cross-correlation function (CCF) between both foci allows one to 
calculate the absolute diffusion coefficents of the fluorescently labelled 
species without further referencing or calibration [91, 118]. 
The 2f-FCS experiments were performed on cell lysates from COS-7 cells, 
transfected with 2 µg plasmids, encoding eGFP, STAT3-eGFP or ΔNTD- 
STAT3-eGFP. Cells were lysed in BRIJ-96V lysis buffer (lacking glycerol).  
 
 
BRIJ-96V-lysisbuffer:  0.1 M  Phosphate buffer, pH 8.0   
     0.5 %  BRIJ-96V 
     1.5 %  Glycerol 
     0.5 mM EDTA 
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Measurements were carried out using a setup based on a standard 
confocal epi-fluorescence microscope [119]. eGFP and eGFP-tagged fusion 
protein constructs were excitated with a 470 nm laser beam (LDH-P-C-
470B). Fluorescence emission light was split from the excitation light by 
using a clearup bandpass filter (490-520 nm). The light was focused by 
confocal optics with a pinhole diameter of 200 µm onto a single photon 
avalanche diode (SPAD, PDM series, Micro Photon Devices, Bolzano, 
Italy). The temperature was controlled using a home-made thermostatted 
device at 25°C [120]. 
 
 
 
 
 
Figure 18: Basic concept of two focus FCS (2f-FCS) and the representative 
autocorrelation functions (ACFs). The 2f-FCS technique introduced an external ruler 
in the measurement of diffusion properties by generating two laterally shifted and 
overlapping laser foci, with a fixed and well known distance. Analyzing the ACFs in both 
foci and additonally the cross-correlation function (CCF) between both foci, diffusion 
properties of the measured particles can be identified without the need of further 
referencing or calibration.  
 
 
An adequate model [91] for ACF/CCF is given by: 
 
 
 
where δ is the lateral distance between the detection volume centers, t is 
the lag time of correlation, v is particle velocity, x,y and z are Cartesian 
coordinates with z along the optical axis, c is the concentration of the 
fluorescent molecules and D is the diffusion coefficient.  
(1) 
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The functions of κ(z) and w(z) are given by the following equations: 
 
 
and 
 
with 
 
 
 
where λex and λem are excitation and emission wavelengths, n is the 
refractive index of the sample, α is the confocal pinhole radius, ω0 and R0 
are fit parameters [91, 118]. 
 
2f-FCS experiments were performed with three independent samples per 
construct and 120 minutes detection time for each measurement.  
 
The fitting procedure of experimental data is carried out globally for both 
the ACFs and CCF using a single particle diffusion model including triplet 
state correction (without necessity to imply a dual particle diffusion model 
suggesting a second slow-moving component). 
 
The hydrodynamic radius (Rh) of the measured complexes was calculated 
by the Einstein-Stokes relation: 
 
 
 
 
where Rh is the hydrodynamic radius, Κ is the Boltzmann-constant, T is 
the temperature, 𝜂 is the viscosity and D is the diffusion coefficient. 
(2) 
(3) 
(4) 
(5) 
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Molecular mass estimation of the measured particles (assuming spherical 
symmetry) was calculated with the known molecular mass of eGFP (27 
kDa) using the following equation: 
 
 
 
 
where MM is the molecular mass, and D is the diffusion coefficient from 
2f-FCS experiments. 
 
2.5.8.	  Förster	  resonance	  energy	  transfer	  (FRET)	  
 
FRET is a widely used technique in cell biology to visualize and detect 
direct protein-protein, ligand-receptor or receptor-receptor interactions, 
but also applied in the design of biosensors to monitor ion concentrations 
[121] or to follow activities of protein kinases or small GTPases [122].  
FRET can be detected in several ways and with different approaches, but 
in general three oftenly used strategies can be distinguished: acceptor 
photobleaching (APB), sensitized emission (SE) and fluorescence lifetime 
imaging (FLIM). 
In this work we applied the acceptor photobleaching (APB) method 
(Figure 19). In APB, the acceptor fluorophore is selectively bleached 
(photochemical destruction leads to the permanent loss of the acceptor 
fluorophore´s ability to emit fluorescence) with a strong laser pulse in a 
defined area (region of interest). During the bleaching procedure, the 
fluorescence intensities of the donor fluorophore are analyzed before (Dpre) 
and after the bleaching procedure (Dpost).  
 
The difference between these donor intensities enables the calculation of 
the FRET efficiency (FRETeff) [123] using the following equation: 
 
 
 
 
 
where Dpre and Dpost are the donor fluorescence intensities before and after 
photobleaching respectively. 
	  
(6) 
(7) 
   
 
42 
 
A.	  
 
 
 
B.	  
 
Figure 19 (A) Acceptor photobleaching (APB) FRET. Representative confocal 
images of fixed HeLa cells expressing SNAP-tag-eGFP fusion construct (positive FRET 
control, SNAP-tag is labelled with TMRstar substrate). Images were captured 
simultaneously and bleaching was performed in TMRstar (acceptor) channel. FRET was 
visualized as an increase in eGFP (donor) fluorescence. (B) Fluorescence intensity 
traces from the representative images. Two eGFP / TMRstar image pairs were 
collected before photobleaching in TMRstar channel and fluorescence intensity changes 
are followed over time. Bleach pulse is indicated by arrow.  
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In the FRET measurements, HeLa cells were examined with a LSM 710 
confocal microscope (Carl Zeiss, Germany) using 40×, 1.1 NA water 
immersion objective with 3× zoom, and 512×512 pixel resolution. Emission 
filters were 505-550 nm for 488 nm excitation (eGFP detection, donor 
channel), and 575-616 nm for 561 nm excitation (TMRstar detection, 
acceptor channel). Images were collected using multi-track mode, with 2% 
laser intensity. Two eGFP / TMRstar image pairs were collected before the 
photobleaching (Figure 19B). Bleaching was performed in a rectangular 
region of interest (ROI) in TMRstar channel using the 561 nm laser line at 
maximum laser power (100% transmission) for 100 iterations (Figure 19A 
and B). 
Cells displaying comparable levels of eGFP and TMRstar were selected for 
FRET analysis to avoid the artifacts and interfererences from the different 
donor-to-acceptor ratios. The measurement setup was established and 
optimized from the experiments based on the positive control.  
FRET efficiencies (%) were calculated using Zen software (Carl Zeiss, 
Germany), based on the equation described before (in section 2.5.8, 
equation 7), taken into account the threshold and background noise in 
each channel. 
 
For live cell FRET imaging, HeLa cells were plated and seeded on eight 
well µ-Slides (Ibidi, Germany) and 24 hours after transfection were placed 
in the cell incubator of Zeiss LSM 710 microscope (Carl Zeiss, Germany) at 
37°C and 5% CO2. FRET measurements were performed using the same 
setup (gain settings, resolution, optical components) as described before. 
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3. Results	  
 
3.1. Characterization	  of	  STAT3	  fusion	  protein	  constructs	  	  
 
To investigate the homodimerization of STAT3 with FRET imaging we 
applied eGFP (enhanced green fluorescent protein) as donor fluorophore, 
and SNAP-tag, reacted with TMRstar substrate (cell permeable 
fluorescent label, based on tetramethylrhodamine) as acceptor molecule.  
To get access to all possible FRET pair combinations, the target protein 
was labelled N- or C-terminally with the donor or with the acceptor 
fluorophore representing four different fusion protein constructs for the 
experiments (Figure 20). 
 
 
 
 
 
Figure 20: Summary of differently labelled STAT3 constructs used in FRET 
experiments. eGFP-tagged STAT3 proteins serve as donors, SNAP-tag fusion constructs 
labelled with TMRstar substrate are the acceptor molecules. All four donor/acceptor 
fusion proteins were used in different combinations as FRET pairs in this study. 
 
To study the expression and functional properties of STAT3 fusion 
constructs, HeLa cells were transfected with plasmids encoding SNAP-
STAT3, STAT3-SNAP, eGFP-STAT3 or STAT3-eGFP. Cells were 
stimulated with IL-6 and soluble IL-6 receptor (sR) for 30 minutes or left 
untreated, lysed and analyzed by immunoblotting (Figure 21A). 
After cytokine stimulation, all constructs showed specific phosphorylation 
at the tyrosine residue 705, demonstrating that labelling with eGFP or 
SNAP-tag (N- or C-terminally) does not interfere with the phosphorylation 
of the fusion protein. After stripping, the blot was reprobed with antibody 
against STAT3 (Figure 21A lower panel).  
For further characterization, differently tagged STAT3 proteins were 
expressed in HeLa cells and the nuclear translocation (as a consequence of 
activation) was followed in real time with confocal microscopy after IL-
6/sR addition (Figure 21B). 
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All four constructs accumulated in the nucleus in response to cytokine 
treatment, indicating that tagging or labelling does not affect the 
activation or the transport of the labelled STAT3 molecules. 
 
 
 
 
 
Figure 21: (A) Functional analysis of STAT3-tag constructs. HeLa cells were 
transfected with the indicated expression vectors encoding SNAP-STAT3, STAT3-SNAP, 
eGFP-STAT3 or STAT3-eGFP. Cells were stimulated with 20 ng/ml IL-6 and 500 ng/ml 
soluble IL-6 receptor (sR) for 30 minutes, or left unstimulated. Lysates were analyzed by 
western blotting using STAT3 phosphotyrosine 705 (STAT3-pY) and STAT3 specific 
antibodies. (B) Ligand induced nuclear accumulation of STAT3 fusion proteins. 
Localization of the fluorescently labelled STAT3 followed in real time after stimulation 
with 20 ng/ml IL-6 and 500 ng/ml soluble IL-6 receptor using confocal microscopy in 
living HeLa cells. Bars, 10 µm. 
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In summary the results confirmed that fluorescence labelling of STAT3 
(N- or C-terminally) does not interfere with the activation or nuclear 
translocation of the protein, which is in good agreement with previously 
published data from our laboratory [81] and from others [124]. Thus, the 
fusion proteins represent functional molecules for further experiments. 
 
3.2. Control	  experiments	  for	  acceptor	  photobleaching	  FRET	  
(APB	  FRET)	  
 
To monitor the interactions and conformational changes between two 
fluorescently labelled STAT3 molecules, we analyzed FRET with acceptor 
photobleaching technique (Figure 22). In general, when a suitable donor 
and acceptor fluorophore are in close proximity, non radiative energy 
transfer (FRET) can occur between the molecules.  
 
 
 
 
 
Figure 22: Acceptor photobleaching FRET (APB FRET). As positive FRET control, 
TMRstar labelled SNAP-tag-eGFP fusion construct (TMRstar-eGFP) showed specific 
increase of eGFP (donor) fluorescence after acceptor (TMRstar) bleaching in a 
rectangular region of interest, as it is visualized in a pseudocolor image of eGFP intensity 
changes. In the negative control, where eGFP was coexpressed with TMRstar-STAT3, no 
intensity changes in eGFP signal was visible after bleaching of TMRstar. Bars, 10 µm. 
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Disruption of the energy transfer by selective bleaching of acceptor 
molecules (TMRstar) leads to an increase in donor (eGFP) fluorescence 
signal as a response to loss of the quenching effect.  
The intensity changes in donor fluorescence were followed over time, prior 
and after the photobleaching procedure (Figure 22), quantified (Figure 23) 
and applied to determine and analyze direct interactions or proximity 
changes in the measured samples.   
 
Although eGFP is a well documented donor fluorophore in various FRET 
systems [125, 126] and SNAP-tag technology is also well established in 
time-resolved FRET (TR-FRET) applications [127], combination of the two 
labelling methods for quantitative fluorescence imaging in biological 
systems is not typical. 
There are publications reporting the use of eGFP-tetramethylrhodamine 
(TMR) dye pair for FRET detection [128, 129], but (to our knowledge) 
there is no published data from the combined use of eGFP and TMR-
labelled SNAP-tag for FRET applications. To take this into consideration, 
essential control experiments were performed.  
To set up the experimental conditions for FRET detection, background and 
maximal FRET signal were analyzed on the appropriate negative and 
positive FRET controls (Figure 23).  
 
 
 
 
 
 
Figure 23. Representative FRET control experiments. eGFP alone, as donor 
fluorophore coexpressed with TMRstar-STAT3 construct served as negative control in   
FRET measurements (FRET efficiency: 2.28±1.01%). The positive control consisted of  
TMRstar-eGFP fusion contruct, where SNAP-tag was labelled with TMRstar substrate as 
acceptor fluorophore (FRET eff.: 17.55±4.84%). (N: 20 cells) 
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As negative control, eGFP was coexpressed with TMRstar-STAT3, where 
only a low FRET signal (2.28±1.01%) was detectable. 
Additonal controls (Figure S1 in supporting material) including Cox8A 
(cytochrome oxidase 8-2 subunit, mitochondrial localization)-TMRstar 
coexpressed with eGFP (Cox8A-TMRstar/eGFP), or donor (eGFP) and 
acceptor (TMRstar-STAT3) alone samples also showed low efficiency 
values as 1.05±0.66%, 0.69±.1.12% and 0.60±0.98% respectively. 
Energy transfer efficiencies of the positive control (SNAP-tag fused to 
eGFP with an eight amino acid long linker) was calculated as 
17.55±4.84%, which represented the highest detectable FRET signal in our 
setup. 
The selection of cells for FRET measurements and microscope settings 
were based on the positive control (relative expression levels of donor and 
acceptor are invariable), to avoid the influence of different donor-to-
acceptor ratios, which beside other parameters (spectral overlap, 
molecular distance, applied method), were shown to effect and have 
impact on the measured FRET efficiency values [130].   
 
3.3. STAT3	  dimerization	  prior	  to	  and	  after	  activation	  	  
 
Dimerization of STAT3 before and after cytokine treatment was followed 
by the analysis of FRET signals between N-terminally, C-terminally, as 
well as N- and C-terminally labelled STAT3 monomers. The results from 
differently combined donor/acceptor pairs are discussed in more details in 
this section. 
 
3.3.1.	  FRET	  between	  N-­‐terminal	  domains	  
 
To follow the orientation of N-terminal domains during the dimerization 
procedure, eGFP-STAT3 and TMRstar-STAT3 were coexpressed (carrying  
donor and acceptor fluorophore at the N-terminus of the host molecule) 
and examined in nuclear and cytoplasmic region of fixed HeLa cells, before 
and after cytokine addition (Figure 24). 
Prior to activation, a significant FRET signal (p<0.001) was detectable 
compared with negative control in both compartments (nucleus: 5.42±2.05%, 
cytoplasm: 5.50±1.91%). 
The results indicate the existence of latent STAT3 dimers and the close 
proximity of N-terminal domains in this structure (Figure 25). 
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Figure 24. FRET efficiencies (%) between N-terminally labelled STAT3 
molecules. Compared to negative control, a significant (p<0.001) FRET signal was 
detectable prior to stimulation in nuclear and cytoplasmic compartment in fixed HeLa 
cells. Stimulation (20 ng/ml IL-6 and 500 ng/ml soluble IL-6 receptor for 30 minutes, to 
provide optimal activation) leads to a decreased FRET signal, indistinguishable from 
negative control in the nuclear compartment (p=0.517). The FRET efficiency of the 
cytoplasmic population remained unchanged (p=0.829) compared to the untreated 
sample. (N: 38-40 cells) 
 
 
Upon activation STAT3 molecules get phosphorylated, translocate to the  
nuclear compartment and acting as transcription factors through binding 
to specific DNA sequences. This activated and nuclearly localized STAT3 
fraction has completely lost the FRET signal, indicating the separation of 
the N-terminal domains in this activated dimer conformation (Figure 25). 
 
 
 
 
 
Figure 25. Possible STAT3 dimer formations. STAT3 monomers prior to stimulation 
dimerize in a parallel or antiparallel manner. In these conformations the N-terminal 
domains are localized close to each other (indicated by arrows). Following cytokine 
addition (+ IL-6), STAT3 molecules get phosphorylated and dimerize in a parallel form 
(stabilized by reciprocal interactions between pTyr residues and SH2 domains) where the 
N-terminal domains are widely separated from each other (NTD: N-terminal domain, 
CCD: coiled-coil domain, DBD: DNA binding domain, LD: linker domain, Tyr: tyrosine 
tail segment, TAD: transactivation domain). 
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FRET efficiencies in the cytoplasmic fraction, showed no significant 
difference (p=0.829) compared to untreated cells, assuming the existence 
of a non-activated/de-activated STAT3 dimer fraction in this compartment 
after 30 minutes of cytokine stimulation. 
These results are in good agreement with data in context of STAT5a [131], 
where similar to our results, loss of FRET signal was detectable after 
stimulation between the N-terminal domains of CFP-STAT5a and YFP-
STAT5a.  
These findings suggest the separation of N-terminal domains upon 
activation, which leads to a structural rearrangement of the dimers to 
form the transcriptionally active conformation (Figure 25), where the N-
terminal regions of each monomer are distantly located [15]. 
 
3.3.2.	  FRET	  between	  N-­‐	  and	  C-­‐terminal	  domains	  
 
We next examined the orientation of N- and C-terminal domains in 
respect to each other using two separate combinations of N- and C-
terminally labelled STAT3 donor/acceptor pairs: eGFP-STAT3 / STAT3-
TMRstar or TMRstar-STAT3 / STAT3-eGFP.  
No differences were detectable between the two donor/acceptor constructs 
(Figure 26) and both measurements revealed an increased FRET signal 
(p<0.001) after stimulation compared to untreated samples. 
 
 
 
 
 
Figure 26. FRET efficiencies (%) from reciprocally tagged STAT3 constructs. 
Increased FRET signals were detectable after activation, indicating the closer proximity 
of N-terminus of one and C-terminus of the other monomer in the activated dimer. (N: 40 
cells) 
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This almost doubled energy transfer efficiency indicates the closer 
orientation of the N-terminal domain of one and C-terminal end of the 
other monomer in the actived STAT3 dimer. 
This close proximity of reciprocal domains could be simply explained as 
the consequence of reciprocal binding of the pTyr residue of one monomer 
to the SH2 domain of the other dimer partner, which decreases the 
distance between the N- and C-termini of the two STAT molecules in an 
activated dimer. 
This hypothesis could also be supported by molecular dynamics simulation 
studies on STAT3 molecules [132, 133]. Their model showed the reciprocal 
binding of the C-terminal fragment to the SH2 domain, where the carboxy 
terminus of one molecule wraps around the SH2 domain of the other 
monomer. This phenomenon could structurally explain the increased 
FRET signal after stimulation. 
 
 
 
 
 
Figure 27. Closely oriented reciprocal domains in the activated STAT3 dimer.  
C-terminal domains are reciprocally associated with SH2 domains of the other monomers 
in the activated dimer and oriented into a closer proximity to the N-terminal regions 
(indicated by arrow).  
 
 
To support our hypothesis, we analyzed a C-terminally truncated STAT3 
form (ΔTAD-STAT3-TMRstar), which lacks the flexible TAD fragment of 
STAT3. This construct showed no increased FRET efficiency after 
activation (Figure S2 in supporting material). 
Taken together, the previously measured separation of N-terminal 
domains upon activation, which is followed by pTyr-SH2 interaction and 
additionally a reciprocal binding between the C-terminal fragment of one 
and the SH2 domain of the other monomer in the activated dimer, 
structurally allows the reciprocal N- and C-termini fragments to get in 
closer proximity (Figure 27), which is detectable as an increased energy 
transfer efficiency in FRET measurements after cytokine addition.  
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3.3.3.	  FRET	  between	  C-­‐terminal	  domains	  
 
In this section we followed the FRET signal between C-terminal domains 
of STAT3 molecules with the coexpression of STAT3-eGFP and STAT3-
TMRstar protein constructs. 
Prior to activation, a strong FRET signal was detectable between the C-
terminal domains of two STAT3 monomers in a preformed dimer structure 
(nucleus: 10.09±1.79%, cytoplasm: 10.26±2.26%) indicating the close 
proximity of the C-terminal regions in this non activated dimer form. 
FRET analysis revealed an increased energy transfer efficiency only in the 
nuclear compartment after cytokine treatment (Figure 28), in comparison 
with  untreated cells (p=0.00016), which is in good agreement with the 
previously published FRET results on STAT3-CFP and STAT3-YFP 
contructs [70, 134].  
 
 
 
 
Figure 28.  FRET efficiencies (%) from C-terminally tagged STAT3 constructs. 
An increased FRET signal was detectable in the nucleus after stimulation, whereas the 
cytoplasmic FRET remained unchanged (p=0.02). This slightly increased efficiency 
proposes the close orientation of the C-terminal domains prior to activation. (N: 36-40 
cells) 
 
 
The cytoplasmic fraction (similar to FRET experiments between the N-
terminal domains of STAT3, Figure 24) showed equivalent proximity of 
the C-terminal fragments as in untreated cells, indicating the presence of 
non-activated dimers in the cytoplasm. 
FRET-results showed the closer orientation of C-terminal domains after 
activation, however this difference compared to non-stimulated sample is 
not that robust to propose the antiparallel orientation, but rather parallel 
to parallel conversion upon activation (Figure 29). 
The antiparallel dimers of STAT1 and STAT5 [131, 135] are stabilized by 
interactions between core fragments involving coiled-coil and DNA-
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binding domains. However this interface was not visible in the 
unphosphorylated STAT3 structure [136] proposing a different type of 
dimer organization.  
This parallel assembly of unphosphorylated STAT3 molecules seems to be 
in contrast to the N-terminal domains mediated antiparallel association of 
non activated STAT1 monomers, where the two SH2 domains are localized 
on the opposite end of the dimer [135]. 
In summary, the FRET results on C-terminally labelled STAT3 constructs 
strongly indicate the parallel-parallel conversion of STAT3 upon 
activation, from preformed to activated dimers (Figure 29). 
In support of this hypothesis, measurements on ΔTAD-STAT3-TMRstar 
and STAT3-eGFP, showed no detectable changes in FRET efficiency after 
stimulation (Figure S3 in supporting material). 
 
 
 
 
 
Figure 29. STAT3 monomers are associated prior and after stimulation in 
parallel arrangements. In both situations, the C-terminal domains are localized at the 
same end of the dimer, representing the parallel oriented dimer formations.  
 
3.3.4.	  Live	  cell	  FRET	  
 
To strengthen our findings, FRET was measured in living HeLa cells 
using the same FRET method (Figure 30A) and experimental setup as in 
fixed cells.  
Similar to measurements in fixed samples, distantly separated N-domains 
were detectable in STAT3 dimer structures in the nuclear region after 
stimulation (FRET efficiency: 2.53 ±1.87%), whereas the cytoplasmic 
population showed the same FRET signal as untreated cells (5.61±2.53%). 
Comparable to our in vitro findings, closer proximity of the reciprocal 
fragments (increased FRET signal betweeen eGFP-STAT3/STAT3-
TMRstar pair) was also detectable, as well as the more closely oriented C-
terminal domains in the nuclear compartment after cytokine addition  
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(11.45±2.13%), while the cytoplasmic fraction showed a less efficient 
energy transfer (8.85±2.45%). 
In summary, the results from living cell FRET experiments confirmed the 
above presented data from measurements on fixed cells. 
 
 
A.	  
 
B.	  
	  	  	  
 
 
 
Figure 30 (A) Representative fluorescence intensity traces from live cell FRET 
measurement. Acceptor (TMRstar) was bleached similar to in vitro measurement, and 
donor (eGFP) emission followed over time. FRET is dectectable only in shorter time 
periods as a consequence of the recovery (by diffusion) of fluorescently labelled particles 
into the bleached area (bleach pulse is indicated by arrow). (B) Summary of live cell 
FRET measurements. Living HeLa cells measured and analyzed at 37°C and 5% CO2 
using the same experimental setup as for fixed samples. (N:14-20 cells) 
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3.4. Role	  of	  the	  N-­‐terminal	  domain	  in	  dimerization	  of	  latent	  
STAT3	  
 
To follow up the homodimer formation of latent STAT3, we were 
interested in the structural requirements for dimerization. 
Structural studies on STAT1 demonstrated the importance of N-domain 
interactions in the formation of unphosphorylated dimers [135]. NTD-
mediated preformed dimers play also a crucial role in the activation of 
STAT4 [137].  
In context of STAT3, the nonphosphorylated core fragment (AA 137-688) 
was shown to exist only as a monomer form [136], indicating similarly to 
other members of the STAT-family the possible involvement of the N-
terminal domains in latent dimerization. 
To test this hypothesis, a deletion mutant of STAT3-eGFP, lacking the N-
terminal domain (STAT3-ΔNTD-eGFP) was generated and investigated by 
fluorescence correlation spectroscopy (FCS) and FRET analysis. 
 
3.4.1.	  Complex	  formation	  of	  latent	  STAT3	  analyzed	  by	  dual-­‐focus	  
fluorescence	  correlation	  spectroscopy	  (2f-­‐FCS)	  
 
Complex formation and diffusion properties of STAT3 and STAT3-ΔNTD 
were analyzed by dual-focus fluorescence spectroscopy (2f-FCS).  
Cos-7 cells were transfected with STAT3-eGFP, STAT3-ΔNTD-eGFP or 
eGFP as a control. Cell lysates were prepared and analyzed with 2f-FCS. 
Fluctuations of the fluorescence signal (which arise from the movement of  
fluorescently labelled particles) were followed over time, and the 
generated autocorrelation functions (ACFs) (Figure 31) evaluated by using 
a one component fitting routine including triplet state correction.  
Mathematical analysis of ACFs provided quantitative information about 
the fluorescently labelled molecules as diffusion coefficient or 
hydrodynamic radius (Table 3).  
The calculated diffusion coefficient of eGFP (1.03±0.04×10-6 cm2/s), derived 
from our measurements, is in good agreement with the previously 
published data of eGFP mobility (0.9×10-6 cm2/s) in aqueous solution [138].  
Full length STAT3 showed slower diffusion (0.54±0.08×10-6 cm2/s) than the 
N-terminally deleted mutant (0.70±0.03×10-6 cm2/s), indicating that the N-
terminally truncated form is deficient in complex formation in 
unstimulated state. 
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Figure 31. Representative autocorrelation functions (ACFs) from the analyzed 
samples using 2f-FCS experiments. Experiments were performed with three 
independent samples per construct and 120 minutes detection time for each 
measurement. Fitting procedure of the experimental data was carried out globally for 
both the ACFs and CCF using a single particle diffusion model including triplet state 
correction (ACF: autocorrelation function, CCF: cross correlation function). 
 
 
To extract informations about the size of the detected complexes, 
hydrodynamic radii (according to Einstein-Stokes relation, Equation 5 in 
section 2.5.7.) and molecular masses (based on the measured diffusion 
coefficient and known molecular mass of eGFP, Equation 6 in section 
2.5.6.) were calculated (Table 3). The resulting molecular mass of STAT3-
ΔNTD-eGFP (88±11 kDa) is in good agreement with the predicted 
molecular mass of monomer STAT3-ΔNTD-eGFP (99 kDa). The apparent 
molecular mass of the full length form, STAT3-eGFP (216±99 kDa) fits 
well with the predicted molecular mass of a  STAT3-eGFP  dimer complex 
(236 kDa). 
 
 
 
 
 
 
Table 3. Diffusion coefficients and molecular masses derived from 2f-FCS 
experiments. Total number of measurements from three independent samples are 
given. The predicted molecular masses were calculated from the known amino acid 
sequences of the proteins. 
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Taken together, the results from 2f-FCS measurements show the ability of 
full-length STAT3 to form dimer complexes in unstimulated state. In 
contrast, the N-terminally deleted STAT3 exists only as a monomer in 
resting cells. 
 
3.4.2.	  Function	  of	  the	  N-­‐terminal	  domain	  in	  dimerization	  of	  latent	  
STAT3	  analyzed	  by	  FRET	   
 
Additionally, FRET was measured between STAT3-ΔNTD-eGFP, and full 
length STAT3 constructs (TMRstar-STAT3 and STAT3-TMRstar) to verify 
the previous findings from 2f-FCS experiments (Figure 32). 
 
. 
 
 
 
Figure 32. Dimerization study of N-terminally deleted STAT3 with wild type 
form. No significant FRET signal was detectable between N-terminally truncated and 
full length STAT3 constructs prior to activation, indicating the importance of the N-
terminal region in dimerization of latent STAT3. After stimulation the increased FRET 
efficiency demonstrates the active dimer formation. (N: 34-40 cells) 
 
 
No significant FRET efficiency was detectable prior to stimulation, 
confirming the defect of N-terminally deleted STAT3 in stable dimer 
formation under latent conditions. 
After cytokine treatment an increased FRET signal between the C-
terminally labelled constructs (nucleus: 8.55±2.31%, cytoplasm: 
8.94±2.65%) demonstrated the capability of the NTD deletion mutant to 
form active dimers. However this dimerization is not visible between the 
reciprocally labelled constructs (nucleus: 2.54±1.23%, cytoplasm: 
2.19±1.73%), possibly due to the structural consequence of the domain 
deletion. 
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In summary, 2f-FCS and FRET measurements identified the N-terminal 
domain of STAT3 to be crucial for the formation of latent dimers (Figure 
33). 
 
 
 
 
 
Figure 33. Deletion of the N-terminal domain prevents the formation of latent 
STAT3 dimers. Truncation of the N-terminal domain inhibits the association of STAT3 
monomers in latent state, but does not affect the phosphorylation driven dimerization 
and DNA-binding in response to cytokine stimulation (for more details see in Ref. [139]). 
 
 
3.5. Characterization	  of	  N-­‐terminal	  domain	  mediated	  
interactions	  
 
To study the function of N-terminal domain in dimerization and 
tetramerization of STAT3, we generated a construct which encodes the N-
terminal fragment of STAT3 (NTD) and for fluorescence detection, fused 
to a SNAP-tag and reacted with the red fluorophore TMRstar (TMRstar-
NTD).  
 
3.5.1.	  Homotypic	  N-­‐terminal	  domain	  interactions	  
 
In the first experiments we ensured that the isolated N-terminal fragment 
is functional and capable to interact with full length STAT3.  
HeLa cells were transfected with constructs encoding TMRstar-NTD and  
eGFP-STAT3 or STAT3-eGFP and analyzed by FRET approach (Figure 
34). A strong FRET signal was detectable (nucleus: 9.34±3.62%, 
cytoplasm: 8.72±2.94%) when the donor fluorophore was localized at the 
N-terminal end of the full length protein.  
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Figure 34. FRET efficiencies (%) of TMRstar-NTD with different STAT3-eGFP 
constructs. FRET results show the capability of the isolated N-terminal construct to 
interact with STAT3, and this interaction is driven in a homotypic manner between the 
N-terminal domains. (N: 30 cells) 
 
 
In contrast, measurements on STAT3-eGFP / TMRstar-NTD resulted in 
low FRET signals (nucleus: 2.64±2.23%, cytoplasm: 2.76±1.94%) indicating 
that the interaction is localized at the N-terminal region of STAT3. 
Control measurements on N-terminally deleted STAT3 (STAT3-ΔNTD-
eGFP), revealed no significant FRET between the two constructs  
(nucleus: 1.76±1.25%, cytoplasm: 1.45±1.57%), indicating that no other 
STAT3 domains are involved in the N-terminal interactions.  
This is in good agreement with GST pull-down assays between N-terminal 
and other STAT3 domain fragments [41], where also no visible interaction 
was detectable with other structural domains of STAT3. 
The results demonstrate the capability of the TMRstar-NTD construct to 
interact with full lenght STAT3, and FRET measurements are marking 
the N-terminal domain as the interaction surface.  
These findings are in good agreement with previous publications showing 
the tendence of N-domains of STATs to dimerize with itself [137].  
 
To further verify and investigate the participation of N-terminal domain 
homotypic interaction in preformed dimer formation, a native gel analysis 
was performed (Figure 35).  
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HeLa cells were transfected with STAT3-YFP and increasing amounts of 
SNAP-NTD encoding expression vector (2-4-8 µg). Cells were left 
unstimulated, lysed, and following the electrophoresis, the gel was 
analyzed with a fluorescence scanner to visualize the STAT3-YFP signal.  
 
 
 
 
 
 
Figure 35. Inhibition of latent dimer formations visualized by native gel 
electrophoresis. The increased expresssion of the isolated N-terminal domain construct 
(SNAP-NTD) affects dimer formations of unphosphorylated full lenght STAT3.  
 
 
The STAT3-YFP alone transfected lysates show clearly two bands, 
representing the dimer and monomer fraction of STAT3-YFP. Transfection 
of  increasing amounts of expression vector encoding SNAP-NTD, lead to 
the inhibition of preformed dimer formation, as it is visible from the 
disappearance of dimer bands. 
 
 
 
 
 
Figure 36. Dissociation of preformed dimers with isolated N-terminal domain. 
Isolated NTD (SNAP-NTD) directly interacts with the N-terminal region of full length 
STAT3. This interaction prevents the formation of NTD-NTD interaction for stabilizing 
the dimer structure, resulting in a monomeric latent STAT3. 
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The results are demonstrating the functionality of the isolated NTD to 
inhibit the dimerization of latent STAT3 molecules. This inhibition 
involves the direct interaction with the N-terminal domain of STAT3, 
which leads to the disruption of dimerization by interference with the 
NTD-NTD interdomain interactions (Figure 36). 
 
3.5.2.	  Importance	  of	  L78	  residue	  in	  dimerization	  of	  N-­‐terminal	  domains	  
 
In the next step we decided to identify the critical amino acid residue 
which plays a crucial role in promoting NTD-NTD interaction and 
stabilizing the preformed dimers. 
For this purpose, we generated a point mutant construct, targeting the 
somatic mutation site found in human inflammatory hepatocellular 
adenomas (IHCAs) in the N-terminal domain of STAT3 at position leucine 
78 [58] (Figure 7).  
Similar to the mutation found in IHCA [58] we generated a L78R 
mutation in the N-terminal domain of STAT3. As in case of the wild type 
construct we fused a SNAP-tag to the mutated NTD and tested the 
interaction capability with full length STAT3 using FRET analysis (Figure 
37). 
 
 
 
 
 
Figure 37. L78 mutated N-terminal domain does not interact with STAT3. A 
single amino acid mutation in the N-terminal domain leads to the destruction of NTD-
NTD interdomain interaction. The detectable FRET efficiencies in both cases are 
undistinguishable from the background, eGFP-STAT3 / TMRstar-NTD L78R ( nucleus: 
1.62 ±1.37%, cytoplasm: 1.37 ±1.31%) and STAT3-eGFP /  TMRstar-NTD L78R (nucleus: 
1.70 ±1.74%, cytoplasm: 1.65 ±1.56%). (N: 30 cells) 
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This single mutation in the N-terminal fragment leads to the complete 
loss of FRET signal between the NTDs of STAT3 (nucleus: 1.62 ±1.37%, 
cytoplasm: 1.37 ±1.31%) in comparison with the previously measured wild 
type form (nucleus: 9.34±3.62%, cytoplasm: 8.72±2.94%, Figure 34). 
The FRET results from L78R mutated N-terminal domain represent the 
direct evidence of L78 residue importance in promoting homotypic NTD-
NTD  interactions between the two domains.  
Involvement of the L78 residue in the dimerization of N-terminal domains 
indicates the existence of a similar dimer interface in case of STAT3, 
which was previously proposed for STAT1, where the NTDs carrying the 
L78 mutation were properly folded but monomer fractions [140].  
 
3.5.3.	  Importance	  of	  L78	  residue	  in	  tetramerization	  
 
The cooperative binding of STAT dimers (tetramer formation) on specific 
DNA target sites is mediated by homotypic interactions between N-
terminal domains [141, 142].   
Tetramerization of STAT3 was shown to be essential for the maximal 
transcriptional activation of the α2-macroglobulin gene promoter [35].  
As we showed previously (section 3.5.1.), the construct encoding the N-
terminal domain of STAT3 fused to a SNAP-tag (SNAP-NTD) are capable 
to interact with full lenght STAT3 and to inhibit the dimerization of latent 
STAT3 by preventing NTD-NTD interdomain interactions. We were 
interested in this inhibitory effect in case of tetramer formations (Figure 
38). 
 
 
 
 
 
 
Figure 38. Tetramerization of STAT3. Phosphorylated STAT3 dimers are able to form 
stable tetramers on specific DNA sequences, mediated by homotypic interactions between 
the N-terminal domains of one dimer and the N-terminal domains from the other dimer 
(indicated by white arrow), and were found to be essential for the maximal activation of 
specific gene promoters. 
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STAT3 tetramerization is analyzed by an α2-macroglobulin promoter 
assay. HepG2 cells were transfected with the reporter construct and with 
expression vectors encoding SNAP-NTD, N-terminal domain construct 
carrying the L78R mutation (SNAP-NTD L78R) or with or 4 µg empty 
vector (Mock).  
Using wild type NTD, a significant downregulation of the α2-
macroglobulin promoter was detectable compared to non-transfected or 
empty-vector transfected samples (Figure 39A). In agreement with our 
results, the same effect was demonstrated with the use of a STAT3 N-
terminal domain based inhibitor peptide (STAT3-Hel2A) on an APRE 
luciferase reporter [129]. In contrast, this inhibition disappeared when the 
N-terminal domain was mutated at the L78 position (Figure 39B).  
These results demonstrate the importance of the L78R residue in N-
terminal domain driven tetramerization of STAT3, indicating the 
involvement of a similar structural interface in this procedure as in  
dimerization of latent STAT3. 
 
 
 
 
Figure 39. (A) Inhibition of α2-macroglobulin promoter activity by SNAP-NTD. 
Cotransfection of wild type N-terminal fragment of STAT3 leads to the prevention of 
tetramer complexes on α2-macroglobulin promoter, as detectable as a decreased induction 
of the promoter. (B) L78R mutation in the N-terminal domain erases the 
inhibitory effect of NTD. The N-terminal fragment carrying a specific point mutation 
(L78R) is not capable to inhibit STAT3-mediated gene induction. Induction of α2-
macroglobulin promoter showed no difference compared to non transfected or empty 
vector transfected sample (p=0.645 and p=0.877 respectively). 
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3.6. Importance	  of	  L78R	  residue	  in	  dimerization	  of	  latent	  
STAT3	  
 
Our previous findings highlighted the importance of N-terminal domain 
interactions in stabilizing the preformed STAT3 dimer. We demonstrated 
the relevance of the L78 residue in this dimer interface, as well as its 
importance in STAT3 tetramer formation. To elaborate these findings, we 
introduced this single mutation to full length STAT3 and applied the 
mutated protein for further analysis. The results from L78R mutated 
STAT3 are described in this section. 
 
3.6.1.	  Characterization	  of	  	  N-­‐terminally	  mutated	  STAT3(L78R)	  
constructs	  
 
For further investigations, two STAT3 constructs were generated carrying 
the specific point mutation at leucine L78 in the N-terminal domain: 
SNAP-STAT3(L78R) and STAT3(L78R)-SNAP (Figure 40). 
 
 
 
 
 
Figure 40. Mutated STAT3 acceptor constructs for FRET imaging. The SNAP-tag 
as a labelling site is located N- or C-terminally on the host molecule carrying the specific 
L78R amino acid substitution in the N-terminal region. 
 
 
To test the functionality and expression of the mutant STAT3 fusion 
constructs, HeLa cells were transfected with plasmids encoding SNAP-
STAT3(L78R) or STAT3(L78R)-SNAP and stimulated with IL-6 and 
soluble IL-6 receptor (sR) or left untreated. The cells were lysed and 
analyzed using western blot technique (Figure 41A). 
Both constructs showed specific phosphorylation on Tyr705 residue after 
cytokine addition as a hallmark of STAT3 activation, and both are 
expressed in HeLa cells as it is detected after reprobing with an antibody 
against STAT3 protein (Figure 41A lower panel). 
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Additionally, nuclear accumulation of the above mentioned fusion proteins 
was studied by live cell imaging (Figure 41B).  
Both constructs, SNAP-STAT3(L78R) and STAT3(L78R)-SNAP (labelled 
with TMRstar substrate) responded with nuclear accumulation to cytokine 
treatment, showing that the mutation in the N-terminal region did not 
affect the transport of the host molecule. 
Taken together, results from the characterization of L78R mutated STAT3 
indicate that the fusion protein constructs carrying the amino acid L78R 
substitution in the N-terminal domain and labelled with SNAP-tag are 
functional and can be used for further investigations. 
 
 
        A. 
 
 
 
 
        B. 
 
 
 
 
 
Figure 41. (A) Functional analysis of N-terminally mutated STAT3 constructs. 
HeLa cells were transfected with the indicated expression vectors encoding SNAP-
STAT3(L78R) or STAT3(L78R)-SNAP. Cells were stimulated with 20 ng/ml IL-6 and 500 
ng/ml soluble IL-6 receptor for 30 minutes or left unstimulated. Lysates were analyzed by 
western blotting using STAT3 phosphotyrosine 705 (STAT3-pY) and STAT3 specific 
antibodies. (B) Ligand induced nuclear accumulation of L78 mutated STAT3 
fusion proteins. Localization of STAT3-SNAP constructs (fluorescently labelled with 
TMRstar) was followed in real time after stimulation with 20 ng/ml IL-6 and 500 ng/ml 
soluble IL-6 receptor using confocal microscopy in living HeLa cells. Bars, 10 µm. 
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3.6.2.	  L78R	  mutation	  prevents	  the	  dimerization	  of	  latent	  STAT3	  in	  vitro	  
and	  in	  vivo	  
 
To analyze the capability of L78R mutated STAT3 constructs to form 
stable dimers prior to cytokine addition, FRET was measured similar to 
wild type measurements on three different FRET pair combinations as: 
eGFP-STAT3 / TMRstar-STAT3(L78R), eGFP-STAT3 / STAT3(L78R)-
TMRstar and STAT3-eGFP / STAT3(L78R)-TMRstar (Figure 42). 
 
 
 
 
 
Figure 42. Summary of FRET results on L78R mutated STAT3 molecules. HeLa 
cells were transfected with the indicated donor/acceptor pairs, labelled with TMRstar 
substrate, stimulated with IL-6 and soluble IL-6 receptor or left untreated, fixed and 
used for FRET imaging. (N: 35 cells) 
 
 
In all three cases, no significant FRET signal was detectable prior to 
stimulation. FRET efficiencies are: eGFP-STAT3 / TMRstar- STAT3(L78R) 
(nucleus: 1.74±1.11%, cytoplasm: 1.76±1.08%),  eGFP-STAT3 / STAT3(L78R)-
TMRstar (nucleus: 1.55±1.15%, cytoplasm: 1.53±1.23%) and STAT3-eGFP 
/ STAT3(L78R)-TMRstar (nucleus: 1.42±1.15%, cytoplasm: 1.60±1.54%). 
The results are clearly indicating the disability of L78R mutated STAT3 
molecules to form dimers in latent state.  
Increased FRET efficiency was detectable after cytokine addition, as is 
clearly visible in the measurements on C-terminally labelled constructs, 
STAT3-eGFP / STAT3(L78R)-TMRstar (nucleus: 6.61 ±1.82%, cytoplasm: 
6.70 ±1.93%) indicating the existence of phosphorylated dimer structures,  
demonstrating that the L78R mutation does not prevent the formation of 
activated STAT3 dimers. 
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To summarize our FRET analysis on L78R mutated STAT3 constructs, the 
results revealed the importance of the L78 residue in the N-terminal 
domain, for promoting NTD-NTD interaction and stabilizing the 
preformed dimers.  
As in case of wild type STAT3, the in vitro findings on fixed cells were 
repeated and confirmed in living cell experiments (Figure 43). 
  
 
 
 
 
Figure 43. Live cell FRET measurements on L78R mutated STAT3 molecules. 
HeLa cells were transfected with the indicated STAT3 constructs, labelled with TMRstar 
substrate, measured and imaged at 37°C and 5% CO2. No significant FRET was 
detectable in all cases prior to stimulation, indicating the in vivo incapability of the L78R 
mutated STAT3 to form dimers prior to cytokine addition. (N:14-20 cells) 
 
 
Similar to fixed samples, no preformed dimerization (significant FRET 
efficiency) was detectable in latent state in all measured samples. The 
measured FRET efficiencies are: eGFP-STAT3 / TMRstar- STAT3(L78R) 
(nucleus: 2.08±0.85%, cytoplasm: 1.56±1.23%), eGFP-STAT3 / STAT3(L78R)-
TMRstar (nucleus: 1.64±1.23%, cytoplasm: 1.21±1.22%) and STAT3-eGFP 
/ STAT3(L78R)-TMRstar (nucleus: 1.80±1.15%, cytoplasm: 1.35±1.12%). 
Stimulation leads to the dimerization and nuclear translocation of the 
constructs as it is detected as a slightly increased FRET signal between 
eGFP-STAT3 / STAT3(L78R)-TMRstar constructs and more clearly visible 
between C-terminally labelled constructs, STAT3-eGFP / STAT3(L78R)-
TMRstar (nucleus: 6.48±2.21%, cytoplasm: 6.42±2.75%). 
In summary, fixed sample and living cell measurements supported our 
conclusion, that the preformed STAT3 dimers are mostly stabilized by 
homotypic interactions driven by the N-terminal domains, and a mutation 
targeting this interface (L78R) prevents these dimer formations. 
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3.7. Function	  of	  preformed	  dimers	  in	  STAT3	  activation	  
 
We identified the N-terminally located amino acid L78, as a key residue 
for promoting dimerization, tetramerization and NTD-NTD interaction 
between STAT3 monomers and dimers. 
In this section we would like to experimentally characterize the possible 
functions of preformed STAT3 dimers in the activation or deactivation 
cycle of JAK/STAT3 signalling. 
From intermolecular FRET measurements on wild type STAT3, we 
propose the existence of a non- or deactivated STAT3 dimer population in 
the cytoplasmic compartment after cytokine stimulation, which shows 
similar structural arrangement as the preassociated monomer forms 
(Figure 44). 
 
 
 
 
 
Figure 44. FRET on wild type STAT3 versus L78R STAT3. After 30 minutes of 
cytokine stimulation, a significant difference (unfilled arrows) was detectable between 
the cytoplasmic and nuclear fractions of activated wild type STAT3 dimers. This 
difference disappeared (filled arrows) by introducing the L78R mutation in the N-
terminal domain of STAT3, indicating the importance of N-terminal interactions in 
promoting these dimer formations.  
 
 
Comparing the results from wild type form and L78R mutated STAT3, 
which is unable to form stable dimers in latent state, we are able to 
analyze and visualize the effect of blocking dimerization of latent STAT3 
on dimerization of activated STAT3 (Figure 44). As it is clearly visible, 
disrupting the capability of STAT3 to form dimers based on N-terminal 
homotypic interactions, the differences in FRET efficiencies of activated 
STAT3 between cytoplasmic and nuclear compartments are not detectable 
anymore: eGFP-STAT3 / TMRstar-STAT3 after stimulation (nucleus: 
2.53±1.87%, cytoplasm: 5.61±2.53%)  versus eGFP-STAT3 / TMRstar-
STAT3(L78R) (nucleus: 1.91±1.22%, cytoplasm: 1.55±1.6%). 
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These disappeared FRET differences are also visible from measurements 
on C-terminally labelled constructs: STAT3-eGFP / STAT3-TMRstar after 
stimulation (nucleus: 12.09±2.52%, cytoplasm: 9.03±2.29%) compared to 
STAT3-eGFP / STAT3(L78R)-TMRstar (nucleus: 6.61±1.82%, cytoplasm: 
6.70±1.93%). These results suggest the existence of NTD-dependent non-
activated STAT3 dimers after cytokine addition, assuming the capability 
of these dimers to by-pass the activation. 
It is well described in context of STAT1, that these N-terminal 
interactions are involved in the reorientation of monomers in the activated 
dimer form to promote dephosphorylation [75]. According to these 
findings, we tested the dependence of the latent dimer form on the 
dephosphorylation mechanism. Cells were transfected with STAT3-eGFP / 
STAT3-TMRstar constructs, pre-treated with phosphatase inhibitors, Na-
vanadate or Halt protease and phosphatase inhibitor cocktail for 15 
minutes and stimulated with IL-6 and sR for 30 minutes, fixed and 
imaged by confocal microscopy (Figure 45). Inhibition of cell phosphatases 
caused an overall reduction of FRET signals, however the non-activated 
dimers were still detectable in cytoplasmic fraction (Na-vanadate: 
4.54±1.45%, Halt inhibitor cocktail: 4.62±1.48%). These results 
demonstrate that preformed STAT3 dimers at some part are connected 
(but not necessary) to the inactivation of STAT3 molecules, indicating the 
ability of dephosphorylated monomers to dimerize after deactivation.  
 
 
 
 
 
Figure 45. Effect of phosphatase inhibition on FRET efficiencies between 
STAT3-eGFP and STAT3-TMRstar. HeLa cells were transfected with STAT3-
eGFP/STAT3-TMRstar FRET pairs, pretreated for 15 minutes with Na-vanadate (1mM) 
or Halt inhibitor cocktail (1:100), stimulated, fixed and analyzed with confocal 
microscopy. (N: 15-20 cells) 
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These findings are in good agreement with previous reports on N-
terminally deleted STAT3, where the truncated mutant showed similar 
dephosphorylation kinetics as the wild type form [143].  
Together with our data, these findings demonstrate the ability of  
dephosphorylated STAT3 monomers to re-dimerize through NTD-NTD 
interactions, however this formation is not necessary for the 
dephosphorylation of activated dimers. 
Furthermore, we tested the involvement of preformed dimers in STAT3 
activation. Cells were transfected with wild type (TMRstar-STAT3) or the 
L78R mutant form, left untreated or stimulated for 30, 60 and 120 
minutes and analyzed by immunoblotting (Figure 46).   
L78R mutated STAT3 showed a reduced expression compared to wild 
type, as it is visualized from reblotting with two different antibodies 
against STAT3 (Figure 46 second and third panel). A similar difference in 
the expression pattern was detected in case of the STAT5a F81A mutant 
in 293T cells [144]. However the pTyr 705 signal (Figure 46 first panel) 
showed almost comparable level of phosphorylation. 
 
 
 
 
 
Figure 46. Disruption of preformed dimers leads to a stronger STAT3 
activation. HeLa cells  were transfected with the indicated expression vectors encoding 
SNAP-STAT3 or SNAP-STAT3(L78R). Cells were stimulated with 20 ng/ml IL-6 and 500 
ng/ml soluble IL-6 receptor for 30, 60 and 120 minutes, or left unstimulated. Lysates 
were analyzed by western blotting using STAT3 phosphotyrosine 705 (STAT3-pY) and 
STAT3 specific antibodies (A: against C-terminal domain of STAT3, B: against N-
terminal domain) and GAPDH as a loading control.   
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This robust activation was also visible in case of N-terminally deleted 
STAT3 forms [143, 145]. 
This difference is even more visible on endogenous STAT3 (Figure 46 first 
panel), where the coexpression of L78R mutant STAT3 leads to an 
enhanced phosphorylation signal, indicating the more effective activation 
of STAT3 when the preformed dimers are disrupted. 
 
In summary, the results based on wild type and L78R mutant STAT3 
showed the involvement of preformed dimers in the negative regulation of 
STAT3 activation.  
This effect could be described by the preassociated dimer structure, which 
is driven by N-terminal domain interactions and possibly additionally 
stabilized by other domains (SH2-domain) [70], resulting in a 
conformation which avoids STAT3 recruitment to the receptor and keeps 
the molecules in the unstimulated state (Figure 47). 
 
 
 
 
 
Figure 47. Function of preformed dimerization in STAT3 activation. In the first 
scenario (1), STAT3 is able to form stable dimers in latent state. This dimer formation is 
stabilized by interactions between N-terminal domains and additional interdomain 
interactions involving the SH2-domains of STAT3. This structural organization prevents 
the recruitment to the receptor. In contrast (2), when preformed dimerization is blocked 
(by a mutation in N-terminal region, highlighted in red) the STAT3 activation is more 
effective. 
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3.8. Intramolecular	  FRET	  measurements	  on	  STAT3	  
 
From the above data we concluded, that latent STAT3 dimers are 
hindered in receptor-mediated phosphorylation and activation. We 
proposed additional interactions involving the SH2-domains that drive the 
dimers into a conformation which blocks the proteins from receptor 
binding. In this section we focused on the role of the SH2-domain in latent 
dimerization of STAT3. 
 
Detecting intramolecular FRET between donor and acceptor fluorophores, 
localized at the same host molecule is a unique way to follow 
conformational changes of the target molecules [146]. We applied this  
intramolecular way of FRET detection to analyze the conformation of an 
SH2 domain mutant STAT3, which carries an arginine to glutamine 
substitution at amino acid position 609 (Figure 48). 
This specific mutation has a strong influence on the overall functionality 
of STAT3 molecule and leads to a non functional SH2 domain [147], 
preventing the phosphorylation of STAT3 [148]. 
Additionally the mutated STAT3(R609Q) protein is unable to form stable 
dimers prior or after stimulation [70, 149], representing a pure monomer 
STAT3 population. 
 
 
 
 
 
 
Figure 48. Mutation of R609 residue targets the SH2 domain of STAT3. R609 
residue is critical (with K591, S611 and S613) to form polar interactions with  
phosphotyrosine 705 motif [15]. Mutation of this residue inhibits the dimer formation of 
STAT3 both in non-activated and activated state. (RCSB Protein Data Bank accession 
number for STAT3 is 1BG1) 
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Our aim was to analyze the effect of R609Q mutation on the overall 
STAT3 structure, and to find a structural answer to the defective 
dimerization. For measuring intramolecular FRET, two double labelled 
STAT3 constructs were generated: eGFP-STAT3-SNAP and eGFP-
STAT3(R609Q)-SNAP (Figure 49). 
 
 
 
 
 
Figure 49. STAT3 constructs used for intramolecular FRET measurements. To 
generate samples for intramolecular FRET analysis, the donor (eGFP, green) and 
acceptor (SNAP-tag coupled with TMRstar substrate, red) were fused on the same host 
molecule N- and C-terminally, respectively. 
 
 
FRET efficiencies from measurements on double tagged wild type STAT3 
(Figure 50) prior (nucleus: 6.68±1.24%, cytoplasm: 6.48±1.39%) or after 
cytokine stimulation (nucleus: 11.39±1.90%, cytoplasm: 13.20±2.78%), 
showed similar results and tendence as the intermolecular FRET results 
on the eGFP-STAT3 / STAT3-TMRstar pair prior or after activation 
(Figure 26). 
 
 
 
 
Figure 50. Summary of intramolecular FRET measurements on wild type and 
R609Q mutated STAT3. Similar to intermolecular FRET results an increased efficiency 
was detectable after cytokine addition, indicating a more sensitive detection of 
intermolecular FRET signal. The R609Q mutated monomer STAT3 form showed similar 
FRET efficiencies as the activated STAT3, indicating the similar orientation of the C- and 
N-terminal domains in mutant monomer as in activated dimer form. (N:30 cells) 
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In the measurements of double-labelled wild type STAT3 we cannot 
exclude the intermolecular FRET signal from our detection system. 
However, the R609Q mutant form which is a pure monomer form, showed 
high intramolecular FRET efficiency values (nucleus: 11.27±2.16, 
cytoplasm: 10.95±2.45) similar to the activated wild type form, indicating 
the same structural organization of this mutant monomer form as the 
activated dimer (Figure 51). 
 
 
 
 
 
 
 
Figure 51. Effect of R609 mutation on STAT3 structure. Mutation of the R609 
residue drives the STAT3 monomer form to a similar structure organization as activated 
dimer. This modification in the SH2 domain leads to the complete inability of STAT3 to 
form dimers prior or after cytokine addition. Proposed localizations of the fluorophores in 
activated dimer and R609Q mutated STAT3 structures are highlighted in green (donor, 
eGFP) and red (acceptor, TMRstar). 
 
 
These results suggest, that mutation of the R609 residue in the SH2 
domain, not only prevents the interaction between pTyr motif and the 
binding pocket in SH2 domain, but leads to a complete reorganization of 
the SH2 fragment (detected as high intramolecular FRET efficiency 
between the N- and C-terminal domains), disrupting the capability of the 
SH2 domain to additionally stabilize the preformed dimers. 
The R609Q mutant reflects a STAT3 form, which structurally mimics the 
activated state, driving the molecule structurally unable to interact with 
activated and latent STAT3 monomer forms (Figure 51). 
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4. Summary	  and	  discussion	  
 
4.1. STAT3	  dimers	  prior	  to	  activation	  
 
One of our major goals was to follow the association of nonphosphorylated 
STAT3 molecules and to structurally identify which regions and domains 
are involved in the stabilization of this dimer. 
Our measurements using dual focus fluorescence correlation spectroscopy 
(2f-FCS) on N-terminally truncated STAT3 (STAT3-ΔNTD) showed that 
deletion of the N-terminal domain leads to the abrogation of latent dimers 
(section 3.4.1.). This inhibited association of unphosphorylated monomers 
was also confirmed by Förster resonance energy transfer (FRET) and 
proposes the contribution of the NTD in promoting dimerization of latent 
STAT3 molecules (section 3.4.2.).   
 
Results from studies on STAT1 [135] and STAT4 [34] demonstrated the 
homotypic interactions of amino terminal domains in promoting 
dimerization and polymerization of these STAT forms.  
 
Our results on constructs encoding only the N-terminal fragment of 
STAT3 (SNAP-NTD) revealed the capability of these domains to 
specifically interact with each other, and no cross reaction was detectable 
involving other domains of STAT3 (section 3.5.1.). These findings are in 
good agreement with previously published data based on other STAT-
family members [73, 137].  
Native gel electrophoresis (section 3.5.1.) showed that dimerization of  
nonphosphorylated STAT3 can be inhibited by the coexpression of wild 
type N-terminal domain (SNAP-NTD) and demonstrated that these 
preformed dimers are mostly stabilized by homotypic NTD-NTD 
interactions, similar  to other members of the STAT family. 
Additionally, we focused on the critical residue in the N-terminal domain, 
which is involved in mediating and stabilizing the homotypic interaction of 
these domains. Based on the somatic mutations found in inflammatory 
hepatocellular tumors [58] targeting the NTDs (L78 residue), we 
generated a construct encoding the N-terminal fragment with a L78R 
amino acid substitution (SNAP-NTD L78R) and tested how this single 
mutation affects the dimerization of N-terminal domains (section 3.5.2.). 
Compared with wild type form, no interaction was detectable with  full 
length STAT3 protein, and suggested the L78 residue as a promising 
target for further investigations. 
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To confirm our findings from the isolated N-terminal domains (SNAP-
NTD constructs), we generated an L78R mutated STAT3 fusion protein 
(section 3.6.1.) to analyze how the full length, but N-terminally mutated 
protein behaves. FRET measurements on L78R mutated STAT3 (section 
3.6.2.) showed no detectable dimers prior to activation (in vitro and in 
vivo) and confirmed the L78 residue importance in forming the NTD-NTD 
interaction.  
 
These results suggest the existence of a similar NTD-NTD interaction 
interface in context of STAT3, which was previously proposed for STAT4 
[140] where the hydrophobic residues L77 and L78 (Figure 52) are 
involved in the homodimerization of these domains. 
 
 
 
 
 
Figure 52. The alternate N-domain dimer of STAT4. This dimer interface is 
suggested by crystal packing. Proteins containing mutations L77A and L78A (indicated 
by arrows) were monomer forms in analytical ultracentrifugation studies (adopted from 
Ref. [140]). 
 
 
To get information, how the monomers are oriented (with respect to each 
other) in the preformed dimer structure, we performed FRET measurements 
on differently combined STAT3 constructs carrying the fluorophores N- or 
C-terminally (Figure 20).  
Measurements on STAT3 when both (donor and acceptor) fluorophores are 
fused to the N-terminal end of the host molecule (section 3.3.1.) revealed 
the closely oriented N-domains as evident from a positive FRET signal.  
 
Similar results were obtained in case of STAT5a [131], which supports the 
theory of N-terminal domain driven stabilization of latent STAT3 dimers.  
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Although the dimerization of NTDs suggests the close proximity of donor 
and acceptor fluorophores, the detected FRET signal between N-
terminally labelled full length proteins was relatively low (nucleus: 
5.42±2.05%, cytoplasm: 5.50±1.91%, Figure 53), similar to studies on 
STAT5a [131]. 
 
 
 
 
 
 
Figure 53. Summary of FRET results on wild type STAT3 in unstimulated state. 
The figure represents the differently combined FRET donor and acceptor pairs with the 
measured FRET efficiencies in nuclear and cytoplasmic regions. The proposed 
localizations of the fluorophores in preformed dimer structure is highlighted in green 
(donor, eGFP) and red (acceptor, TMRstar). 
 
 
This low FRET efficiency could possibly be due to the structural 
background of the N-terminal dimerization interface. As it is visible in 
case of STAT4 (Figure 52), the reconsidered dimer interface of NTDs 
identified the importance of L77 and L78 residues. In this organization, 
the N-terminal residues of NTDs are distantly located which could cause 
at some point this reduced FRET efficiency. 
 
The other point that possibly interferes with the FRET signal includes the 
effect of N-terminal domains interaction on the orientation of fluorophore 
dipoles.  
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As it is well described in previous reports [87], FRET coupling directly 
depends on the angle between donor and acceptor fluorophores, and the 
parallel oriented donor and acceptor molecules yield higher FRET signal, 
compared to the perpendicular oriented fluorophores. These orientation 
changes (or not optimal orientation of  fluorophores), as a consequence of 
N-domain interactions, could additionally affect the FRET efficiency. 
 
FRET measurements on reciprocally (N- and C-terminally) labelled 
STAT3  molecules confirmed the distant localization of the two domains 
(Figure 53). 
Interestingly, we have found the close orientations of carboxy-terminal 
domains of STAT3 with FRET efficiencies (%) of 10.09 (±1.79) and 10.26  
(±2.26)  in the nuclear and cytoplasmic region respectively. Compared with 
transfer efficiency of the positive control (17.55±4.84%), the measured 
FRET signal indicates the closely localized C-terminal domains in 
preformed dimer structure. These findings strongly indicate the parallel 
oriented monomers in preformed dimer state, instead of antiparallel 
formation which was described for STAT1 (section 1.6.1 and [75]). This 
formation could structurally explain how unphosphorylated STAT3 
molecules might be involved in gene expression activation [150] or capable 
of DNA-binding [151] in latent state. 
 
As it is known from previous publications, STAT3 (compared with STAT1 
and STAT4) forms N-domain dimers with low affinity [73], proposing the 
involvement of other structural regions in dimer stabilization. Crystal 
structure of unphosphorylated STAT3 (lacking the NTD and 
transactivation domain) revealed no evidence of other structural domains 
being involved in preformed dimer formation such as coiled-coil domain or 
DNA-binding domain (in contrast to STAT1 and STAT5) [136].  
 
Our measurements on C-terminally truncated STAT3 molecules showed, 
that deletion of the transactivation domain does not affect the formation of 
preformed dimers (Supporting material Figures S2 and S3), as it is 
detected as significant FRET signals between the N- and C-terminal 
(nucleus: 8.46±2.74%, cytoplasm: 8.37±2.41%) as well as between C- 
terminal ends of the dimer (nucleus: 4.75±1.86%, cytoplasm: 4.66±1.89%). 
 
FRET studies on SH2-mutated STAT3 form, STAT3(R609Q), revealed the 
need of an intact SH2 domain for preformed dimerization, and highlighted 
the possibility of SH2 homotypic interactions prior to activation [70]. 
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Our intramolecular FRET measurements on R609Q mutated STAT3 
(section 3.8.) indicate that this single mutation strongly affects the overall 
structure of the SH2 domain (not only the interacting regions with 
phosphotyrosine motif), resulting in a monomer form, which mimics the 
structural organization of the activated STAT3 dimer (Figure 51). This 
modification possibly interferes with regions in the SH2 domain which are 
involved in dimerization of latent STAT3, by generating an additional 
stabilizator interface between the SH2 fragments. 
 
Supporting this hypothesis, previously published data from isolated 
STAT3 SH2 domains showed the ability of the domain fragments to 
dimerize with itself, and even more interestingly these dimerized SH2 
domains were unable to interact with phosphopeptides [152].  
 
This dimerization of SH2 domains independent from phosphopeptide 
binding could structurally explain, why the inhibition of preformed dimers 
leads to an increased STAT3 phosphorylation (Figure 46) and additionally 
could support the existence of non activated dimers in the cytoplasmic 
region after cytokine treatment, while the activated STAT3 dimers are 
mostly located in the nuclear compartment. 
In summary, our findings identify the SH2 domain as a secondary 
stabilizer domain in dimerization of latent STAT3. This parallel dimer, 
formed by the interaction of N-terminal domains, allows the SH2 domains 
to get into a closer proximity and to additionally stabilize the dimer by 
interdomain connections between the SH2 fragments. This dimer 
formation (Figure 47) avoids the monomers from receptor binding and 
subsequently from phosphorylation, representing the preformed STAT3 
dimers as regulators of the cytokine driven activation of STAT3. 
 
In contrast to STAT1, NTD driven association of monomers is not required 
for the dephosphorylation of STAT3 since N-terminally deleted STAT3 
responds similar to IL-6 treatment and displays the same 
dephosphorylation kinetics as wild type form [143].  
 
However our measurements after phosphatase inhibitor treatment, 
showed a decreased FRET signal (Figure 45) in cytoplasmic region after 
cytokine addition indicating that dephosphorylated and inactivated 
STAT3 molecules are able to re-dimerize by the N-terminal domains in a 
latent formation.  
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This dimer organization is not required for the dephosphorylation 
mechanism (in contrast to STAT1) but could possibly regulate the 
hyperactivation of STAT3, by keeping the monomers in a non-activable 
dimer state. This could structurally explain why the constitutively 
activated mutations oftenly targets the SH2-domain and in case of 
inflammatory hepatocellular adenomas (IHCAs), the N-terminal fragment 
of STAT3 (section 1.5.3., Figure 6 and Figure 7) 
 
4.2. Activated	  STAT3	  dimers	  and	  tetramers	  
 
After cytokine stimulation, phosphorylated STAT3 monomers associated 
in an activated dimer form, which is stabilized by the reciprocal 
interactions between a phosphorylated tyrosine residue (pTyr705) of one, 
and the SH2 domain of the other monomer [39]. The phosphorylated 
dimers are transported to the nuclear compartment, bind to specific DNA 
sequences and activate the cytokine driven target gene expression [16]. 
 
We analyzed the dimer formation after cytokine treatment, to detect the 
possible structural differences between preformed and activated dimer 
structures.  
 
N-terminally labelled STAT3 constructs (section 3.3.1.) in the nucleus, 
loose FRET signal between the N-terminal regions, indicating the 
separation of N-terminal domains upon activation, which leads to a 
structural rearrangement of the dimers to form the transcriptionally 
active conformation (Figure 25 and 54) where the N-terminal regions of 
each monomer are distantly located [15]. 
However the cytoplasmic fraction showed a similar FRET signal as the 
unstimulated sample, indicating the existence of a non-activated STAT3 
dimer fraction in the cytoplasmic region (Figure 54, eGFP-STAT3 / 
TMRstar-STAT3, cytoplasm).  
Measurements on reciprocally tagged STAT3 constructs showed an 
increased FRET signal after stimulation, compared with untreated cells, 
indicating the closer orientation of the two separate domains in the 
activated dimer. This closely oriented N- and C-terminal ends from two 
different monomers could be structurally explained by the reciprocally 
oriented C-terminal ends, as a consequence of pTyr705-SH2 interaction, 
as well as by the relocated N-terminal domains, which is caused by the 
disruption of NTD-NTD interactions.  
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Figure 54. Summary of FRET results on wild type STAT3 in activated state. The 
figure represents the differently combined FRET donor and acceptor pairs with measured 
FRET efficiencies in nuclear and cytoplasmic regions. Proposed localizations of the 
fluorophores in activated dimer structures are highlighted in green (donor, eGFP) and 
red (acceptor, TMRstar). 
 
 
We cannot detect any differences in FRET signals between nuclear and 
cytoplasmic fraction for the constructs eGFP-STAT3 / STAT3-TMRstar, 
indicating the existence of an intermediate dimer formation from de-
activated molecules which is stabilized by N-terminal interactions in a 
structural orientation where the N- and C-terminal domains are closely 
localized (Figure 54, eGFP-STAT3 / STAT3-TMRstar, cytoplasm). 
FRET results from STAT3-eGFP / STAT3-TMRstar showed increased 
transfer efficiency upon cytokine stimulation, compared to unstimulated 
sample, similar to publications by others [70, 134] as a consequence of 
SH2-domain mediated dimer formation (Figure 54, STAT3-eGFP / STAT3-
TMRstar, nucleus), where the reduced FRET signal in the cytoplasmic 
region represents the non-activated/de-activated dimer forms.  
 
To confirm our results the measurements were additionally performed in 
living cells (section 3.3.4., Figure 30B). 
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The formation of STAT3 oligomers as tetramers on specific DNA target 
sites is a well described phenomenon, which is mediated by homotypic 
interaction of N-terminal domains [141, 142]. Tetramerization of STAT3 
was shown to be essential for the maximal transcriptional activation of the 
α2-macroglobulin gene promoter, and this cooperation was also stabilized 
by interactions between the N-terminal fragments [35].  
 
We analyzed the inhibition of N-domain interactions on the activation of 
the α2-macroglobulin promoter (section 3.5.3.) with the expression of a 
plasmid construct encoding the N-terminal fragment of STAT3 (SNAP-
NTD). Using wild type NTD, we were able to downregulate the promoter 
activation, most probably by the inhibition of N-domain interactions, 
which results in the disruption of tetramer formations (Figure 36). 
 
 
 
 
 
Figure 55. Tetramerization of STAT3 molecules on DNA. (1) STAT3 tetramers on 
specific DNA sequences are stabilized by homotypic N-terminal interactions (indicated by 
the arrow) (2) Disrupting the NTD-NTD interactions by mutating the L78 residue, 
destabilizes the tetramer formation. 
 
In contrast, this inhibition disappeared when the N-terminal domain was 
mutated at L78 position (Figure 39). These findings suggest a similar 
NTD-NTD interaction interface involved in latent dimer formation, as well 
in tetramerization of STAT3, representing a possible target for inhibitor 
design against the oligomerized STAT3 molecules (Figure 55). 
 
In context of oligomerization it is still an open question is how the N-
terminal domains contribute to STAT3 body formations (section 1.6.2). 
Previous report on STAT1 paracrystals [83] showed the involvement of 
mutual N-domain and pTyr-SH2 domain interactions in the assembly of 
the proteins However, in our hands the N-terminally deleted or L78R 
mutated STAT3 molecules were still able to form nuclear bodies after 
cytokine stimulation. 
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4.3. STAT3	  dimer	  formations	  in	  the	  JAK/STAT3	  pathway	  
 
Our FRET results demonstrated the existence of stable, unphosphorylated 
STAT3 dimers in latent state (Figure 53 and 56) which is in good 
agreement with previously published results [67, 69, 70].  
We found that dimer formation is dominated by homotypic interactions 
between the N-terminal domains, similar to other STATs [135, 140] and 
additionally we identified the L78 residue to be important in promoting 
the association of the NTDs (section 3.5.2.). 
 
 
 
 
 
 
 
Figure 56. Preformed and activated STAT3 dimers in the JAK/STAT3 pathway. 
Monomers are associated in latent state (preformed dimers) in a parallel orientation. 
This dimer is mostly stabilized by homotypic interactions between the N-terminal 
domains, and orientates the monomers in a form, which structurally allows the separate 
SH2 domains to interact with each other (additional stabilization) avoiding the 
monomers from activation (receptor binding). The phosphorylated monomers are 
associated in an activated dimer form (stabilized by pTyr-SH2 interactions) and 
translocated to the nuclear compartment where they bind to specific DNA sequences. 
After inactivation (dephosphorylation) STAT3 is transported to the cytoplasmic region, 
and through an intermediate state, forms latent dimers or monomers. 
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This interaction between N-terminal regions, drives the two monomers 
into a parallel orientation which is stabilized by the SH2 domains. This 
dimer form is structurally inhibited from activation (receptor binding) 
(Figure 47 and Figure 56).  
Activated and phosphorylated STAT3 monomers also dimerize in a 
parallel manner, which is driven and stabilized by pTyr-SH2 reciprocal 
interactions. This activated form translocates to the nucleus and binds to 
DNA. After dephosphorylation, the molecules return to the cytoplasm and 
are stabilized through an intermediate state in a latent parallel dimer 
form (Figure 56). 
5. Conclusions	  and	  perspectives	  
 
 
The central aim of our study was to investigate STAT3 dimerization in 
latent and activated state with single molecule spectroscopy and advanced 
microscopy methods as 2f-FCS or acceptor photobleaching FRET. 
 
In this study we demonstrated the importance of the N-terminal domain 
in the dimerization of latent STAT3 (section 3.4) as well as the role of 
homotypic interactions of NTDs in the stabilization of these dimer forms 
(section 3.5.1).  
 
We identified the relevance of the L78 residue in promoting these 
interactions (section 3.5.2 and section 3.6.2), and additionally the 
participitation of this dimer interface in tetramerization of STAT3 on the 
α2-macroglobulin promoter (section 3.5.3).  
 
We identified the role of preassociated STAT3 dimers in the negative 
regulation of STAT3 activation (section 3.7) and we proposed the SH2 
domain involvement as additional stabilizators in formation of latent 
dimers (section 3.8).  
 
From our FRET results we concluded the parallel association of the non-
activated and activated dimer forms, however the dimeric complexes are 
stabilized by diverse interdomain interactions (Figure 56).  
 
Although our findings indicate the existence of a similar N-terminal 
domain dimer interface in context of STAT3, as in case of other STAT 
family members, this does not rule out the divergent structural 
organization of NTD dimers.  
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This possibility should be analyzed by crystallographic studies on NTD-
dimers of STAT3. More detailed knowledge of NTD-dimer interface(s) of 
STAT3 is indispensable for successful inhibitor design against these 
interaction surfaces. 
 
Based on our results we proposed the SH2-SH2 interaction as a secondary 
stabilizer interface in preformed dimerization. This hypothesis should be 
refined by point mutation studies on the SH2 domain based on the somatic 
mutations found in several diseases such as hyperimmunoglobulin-E 
syndrome (HIES), large granular lymphocytic leukaemia (LGL leukaemia) 
or in inflammatory hepatocellular adenomas (IHCAs) (section 1.5.3) to 
identify key residues in promoting SH2 homotypic interactions and 
structurally answer the effect of these mutations on formation of latent 
dimers, or on the overall STAT3 structure.  
 
The work presented here proposes the structurally similar organizations 
of preformed and activated dimer forms (parallel arrangements). The 
activation requires only a slight turn of the monomers in respect to each 
other in the phosphorylated dimer form as a consequence of pTyr-SH2 
interaction formation. 
 
In context of inhibitor design it could be interesting how STAT3 molecules 
can be kept in „preformed“ state avoiding the molecules from activation, or 
the other way around is there a possiblity to turn or force the activated 
STAT3 dimers to an inactive dimer form. 
 
Another important issue is to analyze the function of the N-terminally 
mutated STAT3 in mouse models, which could possibly explain the roles of 
the N-terminal domain in diverse biological functions. 
 
In case of tetramerization or oligomerization of STAT3, there are still 
some interesting questions to answer, as is tetramerization only formed on 
specific DNA sequences and restricted to tandem STAT3 binding sites, or 
also possible on single canonical sites, as it is proposed for STAT1 [144].  
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Supporting	  materials	  
 
 
 
 
 
 
 
Figure S1. Additional FRET controls.  Additional control measurements on donor 
alone (FRETeff: 0.69±1.12%), acceptor alone (0.60±0.98%) and on Cox8A-TMRstar/eGFP 
cotransfected sample (1.05±0.66%). (N: 20 cells) 
 
 
 
 
 
 
 
 
Figure S2. FRET measurements between eGFP-STAT3 and C-terminally deleted 
STAT3 form (ΔTAD-STAT3-TMRstar). No visible difference detectable in FRET 
efficiencies between untreated (nucleus: 8.46±2.74%, cytoplasm: 8.37±2.41%) and 
stimulated (nucleus: 7.52±2.67%, cytoplasm: 8.24±2.52%) samples. (N: 30 cells) 
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Figure S3. FRET measurements between STAT3-eGFP and C-terminally deleted 
STAT3 form (ΔTAD-STAT3-TMRstar). Untreated sample (nucleus: 4.75±1.86%, 
cytoplasm: 4.66±1.89%) represents similar FRET results as the stimulated sample 
(nucleus: 5.54±1.51%, cytoplasm: 5.45±2.04%). (N: 30 cells) 
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